What is claimed is:

1. A compound represented by Formula (I):

and N-oxides, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof, a nd racemic mixtures, diastereomers and enantiomers thereof, wherein Z is selected from the group consisting of -N(R^OR ² and H;

L is selected from the group consisting of a covalent bond and -N(OR ² )-; wherein, when L is -N(OR ² )-, Z is H; and wherein, when Z is H, L is -N(OR ² )-;

J is selected from the group consisting of a covalent bond, =CH-, -Ci-Csalkyl-, -Co-C ₃ alkyl- Ci-C ₈ heteroalkyl-C ₀ -C ₃ alkyl-, -Co-C3alkyl-C2-C8alkenyl-Co-C ₃ alkyl-, -C ₀ -C ₃ alkyl-C ₂ - C ₈ alkynyl-C ₀ -C ₃ alkyl-, -Co-Cealkyl-aryl-Co-Cealkyl-, -Co-Cealkyl-aryl^-Ceheteroalkyl-, -Co-C ₃ alkyl-C _l -C ₆ heteroalkyl-aryl-Co-C ₆ alkyl-, -Co-C ₃ alkyl-C _l -C ₆ heteroalkyl-heteroaryl- Co-C ₆ alkyl-, -Co-Cealkyl-cycloalkyl-Co-Cealkyl-, -Co-Cealkyl-heterocyclyl-Co-Cealkyl-, ^-Ceheterocyclyl-aryl-Co-Cβalkyl-, ^-Ceheterocyclyl-aryl-Co-Ceheteroalkyl-, -Co- C ₆ alkyl-C4-C6heterocyclyl-Co-C ₆ alkyl-, -Co-Cealkyl-heteroaryl-Co-Cealkyl-, -C ₀ - Cealkylheteroaryl-Co-Ceheteroalkyl-, ^-Coheterocyclyl-heteroaryl-Co-Cealkyl-, -Co- C ₆ alkyl-aryl-C ₂ -C ₆ alkynyl-, -Co-Cealkyl-heteroaryl^-Cealkynyl-, -C ₀ -C ₆ alkyl-aryl-C ₂ - C ₆ alkynyl-C ₂ -C ₆ alkenyl-, -Co-Cealkyl-aryl-C^Cealkenyl-, -C ₀ -C ₆ alkyl-heteroaryl-C ₂ - C ₆ alkenyl-, -Co^alkyl^-Cealkenyl-aryl-Co-Cealkyl-, -Co-C ₃ alkyl-C ₂ -C ₆ alkenyl- heteroaryl-Co-C ₆ alkyl-, -Co-C ₃ alkyl-C ₂ -C6alkynyl-aryl-Co-C6alkyl-, -Co-C ₃ alkyl-C ₂ - Cealkynyl-heteroaryl-Co-Cealkyl-, -Co-Cealkylaryl-aryl-Co-Cealkyl-, -C ₀ -C ₆ alkylaryl- heteroaryl-Co-C ₆ alkyl-, -Co-Csalkyl-heteroaryl-heteroaryl-Co-Csalkyl-, -Co-C ₃ alkyl- heteroaryl-aryl-Co-C ₃ alkyl-, -Co-C ₃ alkyl-aryl-heteroaryl-Co-C ₃ alkyl-, -Co-C ₃ alkyl-aryl- aryl-Co-C ₃ alkyl-, and -Co-Cealkyl-Cs-Cecycloalkyl-Co-Cβalkyl-, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, aryl, heteroaryl, heterocyclyl, and cycloalkyl moiety is optionally substituted, and wherein when J is =CH-, Q is a covalent bond and B is attached through a carbon sp ² to J;

Q is selected from the group consisting of an optionally substituted:

(a-6) , (a-7)

or where possible, an (R,R) or (S, S) enantiomer or a mixture of enantiomers thereof, wherein G and G ¹ are independently selected from carbon and N; the variables /, m, n, o and p denote numbers that are each independently selected from O, 1, 2 or 3 provided that the sum total of 1, m, n, o and p is 4, 5, 6 or 7, such that the group represented by Q comprises a 6, 7, 8 or 9 membered bridged or fused heterocyclyl, respectively, and further provided that when G and G ¹ are both N then the sum total of / and o is not zero, and the sum total of m and/? is not zero, and wherein n is an integer ranging from O to 3; (preferably, Q comprises a 7 or 8-membered ring; in one particular embodiment, n is zero, such that Q comprises a fused bicyclic ring);

U is selected from the group consisting of -Co-C ₈ alkyl-C(0)-Co-C ₃ alkyl-, -Ci-Csalkyl-, -Co- C ₈ alkyl-N(R ³ )-C(O)-C ₀ -C ₃ alkyl-, -C ₀ -C ₈ alkyl-0-C(0)-Co-C ₃ alkyl-, -Co-C ₈ alkyl-N(R ³ )-

C(S)-Co-C ₃ alkyl-, -Co-C ₈ alkyl-0-C(S)-Co-C ₃ alkyl-, -Co-C ₈ alkyl-N(R ³ )-S(0) ₂ -Co-C ₃ alkyl-, -Co-Cgalkyl-heterocyclyl-Co-Csalkyl-, a covalent bond and -O-C ₂ -C ₄ alkyl-; and

U ¹ is selected from the group consisting of H, -C(R ¹ XR ² )-, -C ₀ -C ₈ alkyl-C(O)-C ₀ -C ₃ alkyl-, -Ci-C ₈ alkyl-, -Co-C ₈ alkyl-N(R ³ )-C(0)-C ₀ -C ₃ alkyl-, -C(R ¹ )(R ² )-N(R ³ )-C(O)-C ₀ -C ₃ alkyl-, -C(R ¹ )(R ² )-C(O)-C ₀ -C ₃ alkyl-, -Co-C ₈ alkyl-0-C(0)-C ₀ -C ₃ alkyl-, -C(R ¹ )(R ² )-0-C(0)-Co- C ₃ alkyl-, -Co-C ₈ alkyl-N(R ³ )-C(S)-C _o -C ₃ alkyl-, -C ₀ -C ₈ alkyl-O-C(S)-C ₀ -C ₃ alkyl-, -C ₀ - C ₈ alkyl-N(R ³ )-S(O) ₂ -C ₀ -C ₃ alkyl-, -Co-Csalkyl-heterocyclyl-Co-Csalkyl-, a covalent bond, (R ³ )(R ^3a )N-C ₂ -C ₄ alkyl-, -O-C ₂ -C ₄ alkyl-, and R ³ -O-C ₂ -C ₄ alkyl-; or

Q is selected from the group consisting of a covalent bond, -Ci-Csalkyl-, -Ci-Csalkyl-, -Ci- Csheterocyclyl-, =N-O-, -Co-C ₆ alkyl-N(R ³ )-C _o -C ₃ alkyl-, -Co-C ₆ alkyl-0-Co-C ₃ alkyl-, -C ₀ - C ₆ alkyl-S(0)o. ₂ -Co-C ₃ alkyl-, -Co-Cealkyl-heterocyclyl-Co-Qalkyl-, -C ₀ -C ₆ alkyl-C(O)-C ₀ - C ₃ alkyl-, -Co-C6alkyl-0-Co-C ₃ alkyl-, -Co-C ₆ alkyl-cycloalkyl-Co-C ₃ alkyl-, -C ₀ -C ₆ alkyl- N(R ³ )-C(O)-cycloalkyl-C ₀ -C ₃ alkyl-, -Co-C ₆ alkyl-N(R ³ )-cycloalkyl-C ₀ -C ₃ alkyl-, -C ₀ - C ₆ alkyl-S(0)o-2-N(R ³ )-cycloalkyl-C ₀ -C ₃ alkyl-, -Co-C ₆ alkyl-N(R ³ )-C(0)-N(R ³ )- cycloalkyl-C ₀ -C ₃ alkyl-, -Co-C ₆ alkyl-0-C(0)-0-cycloalkyl-C ₀ -C ₃ alkyl-, -C _o -C ₆ alkyl- N(R ³ )-C(O)-O-cycloalkyl-C ₀ -C ₃ alkyl-, -Co-C6alkyl-(CR ³ =CR ³ )i. ₂ -Co-C ₆ alkyl-, -C ₀ - C ₆ alkyl-(C≡C)i. ₂ -Co-C6alkyl-, -Co-C6alkyl-N(R ³ )-C(0)-C ₀ -C ₃ alkyl-, -Co-C ₆ alkyl-N(R ³ )- C(0)-alkenyl-Co-C ₄ alkyl-, -Co-C ₆ alkyl-C(0)-N(R ³ )-C ₀ -C ₄ alkyl-, -C ₀ -C ₆ alkyl-SO ₂ -N(R ³ )- Co-C ₃ alkyl-, -Co-C ₆ alkyl-N(R ³ )-S0 ₂ -C ₀ -C ₃ alkyl-, -Co-C ₃ alkyl-N(R ³ )-S(0) ₂ -N(R ³ )-C ₀ - C ₃ alkyl-, -Co-C ₆ alkyl-S-Co-C ₃ alkyl-, -C ₀ -C ₆ alkyl-S(O)-C ₀ -C ₃ alkyl-, -C ₀ -C ₆ alkyl-S(O) ₂ - Co-C ₃ alkyl-, -Co-C ₆ alkyl-N(R ³ )-C(0)-N(R ³ )-Co-C ₃ alkyl-, =N-0-C ₀ -C ₃ alkyl-, -heterocyclyl-Co-Csalkyl-heterocyclyl-Co-Csalkyl-, -S0 ₂ -Co-C6alkyl-heterocyclyl-Co- C ₃ alkyl-, -C(O)-C ₀ -C ₆ alkyl-bridged heterocyclyl-C ₀ -C ₃ alkyl-, -N(R ³ )-C(O)-C ₀ -C ₆ alkyl- heterocyclyl-Co-C ₃ alkyl-, -0-C(0)-Co-C ₆ alkyl-heterocyclyl-C ₀ -C ₃ alkyl-, -N(R ³ )-C(S)-Co- C ₆ alkyl-heterocyclyl-C ₀ -C ₃ alkyl-, -0-C(S)-Co-C ₆ alkyl-heterocyclyl-C ₀ -C ₃ alkyl-, -N(R ³ )- S(0) ₂ -Co-C ₆ alkyl-heterocyclyl-Co-C ₃ alkyl-, -Co-C6alkyl-heterocyclyl-Co-C ₃ alkyl-S02- N(R ³ )-, -C ₀ -C ₆ alkyl-heterocyclyl-Co-C ₃ alkyl-C(0)-N(R ³ )- and -Co-Cealkyl-heterocyclyl- Co-C ₃ alkyl-C(0)-0-, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl,

heterocyclyl, aryl and heteroaryl moiety is optionally substituted; wherein selected from the group consisting of b- Ia to b- Ik and b-1 to b-125, and wherein when Q

is attached to via =N-O-, or =N-0-Co- ₃ alkyl, it is attached through carbon Sola-

Penna et al. in , and wherein each alkyl, heteroalkyl, cycloalkyl, heterocyclyl and alkenyl moiety is optionally substituted; and wherein when Q is a covalent bond and

J is attached to via =CH-, then it is attached through carbon sp 2 in or

when selected from the group consisting of b-1 to b-121 and is attached to Q via a

N in then Q is selected from the group consisting of a covalent bond, -C(O)-C ₁ - C ₃ alkyl-O-, -Ci-C ₈ alkyl-, -C2-C ₆ alkyl-N(R ³ )-Co-C ₃ alkyl-, -C ₀ -C ₆ alkyl-heterocyclyl-C ₀ - C ₃ alkyl-, -Co-C ₆ alkyl-C(0)-Co-C ₃ alkyl-, -Co-Cealkyl-O-Co-Csalkyl-, -Ci-C ₆ alkyl- (CR ³ =CR ³ )i_ ₂ -C ₀ -C ₆ alkyl-, -Ci-C ₆ alkyl-(C≡C)i. ₂ -Co-C ₆ alkyl-, -C ₂ -C ₆ alkyl-N(R ³ )-C(O)- Co-C ₃ alkyl, -C ₂ -C ₆ alkyl-N(R ³ )-C(O)-alkenyl-C ₀ -C ₃ alkyl, -Co-C ₆ alkyl-C(0)-N(R ³ )-C ₀ - C ₄ alkyl-, -C(0)-0-Co-C ₄ alkyl, -C ₀ -C ₆ alkyl-S(0) ₂ -N(R ³ )-Co-C ₃ alkyl, -C ₂ -C ₆ alkyl-N(R ³ )- S(0) ₂ -Co-C ₃ alkyl, -C ₂ -C ₃ alkyl-N(R ³ )-S(0) ₂ -N(R ³ )-Co-C ₃ alkyl-, -C ₂ -C ₆ alkyl-S-C ₀ - C ₃ alkyl, -C ₂ -C ₆ alkyl-S(O)-C ₀ -C ₃ alkyl, -C ₀ -C ₆ alkyl-S(O) ₂ -C ₀ -C ₃ alkyl, -C ₂ -C ₆ alkyl-N(R ³ )- C(O)-N(R ³ )-C ₀ -C ₃ alkyl, -C2-C ₃ alkyl-C=N-0-Co-C ₃ alkyl, -SO ₂ -C ₀ -C ₆ alkyl-heterocyclyl- Co-C ₃ alkyl-, -C(0)-Co-C ₆ alkyl-heterocyclyl-Co-C ₃ alkyl-, -C ₂ -C ₄ alkyl-N(R ³ )-C(O)-C ₀ - C ₆ alkyl-heterocyclyl-C ₀ -C ₃ alkyl-, -C ₂ -C ₄ alkyl-0-C(0)-Co-C ₆ alkyl-heterocyclyl-Co- C ₃ alkyl-, -C ₂ -C ₄ alkyl-N(R ³ )-C(S)-Co-C ₆ alkyl-heterocyclyl-C ₀ -C ₃ alkyl-, -C ₂ -C ₄ alkyl-O- C(S)-Co-C ₆ alkyl-heterocyclyl-C ₀ -C ₃ alkyl-, -C ₂ -C ₄ alkyl-N(R ³ )-S(0) ₂ -Co-C ₆ alkyl- heterocyclyl-Co-C ₃ alkyl-, -Co-C ₆ alkyl-heterocyclyl-C ₀ -C ₃ alkyl-S(0 ₂ )-N(R ³ )-, -C ₀ - C ₆ alkyl-heterocyclyl-Co-C ₃ alkyl-C(0)-N(R ³ )- and -Co-C ₆ alkyl-heterocyclyl-Co-C ₃ alkyl- C(O)-O-, wherein each alkyl, heterocyclyl and alkenyl moiety is optionally substituted, and wherein the heterocyclyl moiety is optionally bridged with -(CH ₂ )o- ₃ -;

R ¹ and R ² are independently selected from the group consisting of -H, Ci-Cβalkyl, aryl, heteroaryl, heterocyclyl, cycloalkyl and a protecting group; each R is independently selected from the group consisting of -H, alkyl, Co-C ₃ alkyl- heterocyclyl, C ₁ -C ₃ alkyl-C ₂ -C ₆ alkenyl, Ci-C ₃ alkyl-C ₂ -C ₃ alkynyl, -C ₂ -C ₄ alkyl-OR ¹ , -C ₂ - C ₄ alkyl-NR ^3b R ^3c , -C ₂ -C ₄ alkyl-NR ¹ R ² , heteroalkyl, C ₀ -C ₆ alkylheteroaryl, C(O)CF ₃ , -C(O)-NH ₂ , -C(O)-NR ^3b R ^3c , -C(O)-NR ¹ R ² , -C(O)-OR ¹ , -S(O) ₂ -NR ¹ R ² , -S(O) ₂ -R ¹ , -C(O)- R ¹ , -C ₃ -C ₆ cycloalkyl, -C ₀ -C ₃ alkyl-C ₃ -C ₇ cycloalkyl, -Ci-C ₆ alkylaryl, aryl, C ₀ -C ₃ alkyl-

heteroaryl and heteroaryl, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl moiety is optionally substituted with from one to three independently selected substituents; each R ^3a is independently selected from the group consisting of -H, alkyl, heterocyclyl, C ₂ - Cβalkenyl, C ₂ -C ₃ alkynyl, C ₂ ^aIkVl-OR ¹ , heteroalkyl, heteroaryl, Co-Cβalkylheteroaryl, C(O)CF ₃ , -C(O)-NH ₂ , -Cs-Cecycloalkyl, -alkyl-Cs-Cecycloalkyl, -Ci-C ₆ alkylaryl, aryl, alkylheteroaryl and heteroaryl, covalent bond, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl moiety is optionally substituted; wherein R ³ and R ^3a , together with the atom to which they are attached, optionally form a heterocyclic ring, wherein the heterocyclyl moiety is optionally substituted; wherein R ^3b and R ^3c , together with the atom to which they are attached, optionally form a heterocyclic ring, wherein the heterocyclyl moiety is optionally substituted;

provided that absent when Q is structure (a-1), (a-2), (a-3), (a-20) or when U is H, N(R ³ )(R ^3a )-C ₂ -C ₄ alkyl- or R ³ -O-C ₂ -C ₄ alkyl-;

selected from the group consisting of hydrogen, aryl, aryl-alkyl-, heteroaryl, heteroaryl-alkyl-, heterocyclyl, cycloalkyl, heterocyclyl-alkyl, cycloalkyl-alkyl, C ₁ - Cioalkyl, (aryl) ₂ -CH-C ₀ -C ₆ alkyl-, (aiyl)(heteroaiyl)CH-C ₀ -C ₆ alkyl- and (heteroaryl) ₂ CH- C ₀ -C ₆ alkyl-, each of which is optionally substituted; or

a radical selected from the group consisting of

(b-79)

wherein are independently selected from phenyl or a 5- or 6-membered heteroaryl, wherein each of which is optionally substituted with one to three substituents;

provided that when is selected from the group consisting of hydrogen, aryl, aryl- alkyl-, heteroaryl, heteroaryl-alkyl-, heterocyclyl, cycloalkyl, heterocyclyl-alkyl, cycloalkyl-alkyl, Ci-Cioalkyl, (aryl) ₂ -CH-C ₀ -C ₆ alkyl-, (aryl)(heteroaryl)CH-C ₀ -C ₆ alkyl- and (heteroaryl) ₂ CH-Co-C ₆ alkyl-, each of which is optionally substituted, then Q is selected from the group consisting of a-3, a-4, a-5, a-6, a-7, a-8, a-9, a-10, a-11, a-12, a- 13 and a-14, wherein each A is independently selected from the group consisting of N, -N-oxide, -CH= and

-C(R ⁴ )=, wherein no more than two A per 5 or 6 mem Lbbeerreedd rriinngg aarree NN i inn aa group, and wherein no more than one A is -N-oxide; the group M^M ² is selected from the group consisting of a covalent bond, -N(R ³ )CH2-, -CH ₂ N(R ³ )-, -S(0)o-2-CH ₂ -, -CH ₂ S(OV ₂ -, -0-CH ₂ -, -CH ₂ -O-, -C(O)N(R ³ )-, -C(O)-O-, -C(O)-CH ₂ -, -CH(OH)-CH ₂ -, -CH(F)-CH ₂ -, -CH ₂ -C(O)-, -CH ₂ -CH(OH)-, -CH ₂ -CH(F)-, -N(R ³ )-C(0)-, -SO ₂ N(R ³ )-, - N(R ³ )SO ₂ -, -CH(R ⁴ )CH ₂ -, -CH ₂ CH(R ⁴ )-, -N=C(R ⁴ )-, -C(R ⁴ )=N-, -CH ₂ -CH ₂ -, -CH=CH-, -CH(R ³ )-CH(R ³ )-, -C(R ³ )=C(R ³ )-, -C(R ⁴ )=C(R ⁴ )-,

-CF=CH-, -CH=CF-, , -CH ₂ -, -C(R )(R )-, -S(O) _0-2 -, -N(R ³ )-, or absent;

M is selected from the group consisting of ,

or M ³ is , wherein Q is attached to via =N-0-, or =N-O-C _0-3 alkyl, or J is

attached to via =CH-, wherein * represents the point of attachment to Q;

M is selected from the group consisting of

and covalent bond ;

wherein, when M -M is a covalent bond, M is selected from the group consisting of

the groups D^D ² and D ^la -D ^2a are selected from the group consisting of

wherein, * represents the point of attachment to Q;

D ³ is selected from the group consisting of a covalent bond,

; wherein the and

are optionally substituted;

D is selected from the group consisting of ^; wherein the

is optionally substituted;

the group E^E ² is selected from the group consisting of

wherein * represents the point of attachment to Q; and E ³ is selected from the group consisting of -C(O)-, -C(S)-, -CH ₂ -, -C(OH) ₂ - and -C=N(R ³ )-; and

R ⁴ is independently selected from the group consisting of -H, d-C ₆ alkyl, C ₂ -C ₆ alkenyl, C ₂ - C ₆ alkynyl, Ci-C ₆ alkyl-R ³ , -C ₀ -C ₆ alkyl-OR ³ , -Co-Cealkyl-OR ¹ , -C ₀ -C ₆ alkyl-C(O)-OR ³ , -Co-C ₆ alkyl-C(0)NR ³ R ^3a , -CH=CH-C(O)-OR ³ , -CH=CH-C(O)-N(R ³ )(R ^3a ), -N(R ³ )- C(O)-CF ³ , -N(R ³ )-C ₂ -C ₆ alkyl-N(R ³ )(R ^3a ), -C ₀ -C ₆ alkyl-N(R ³ )(R ^3a ), -N(R ³ )-C(O)-Ci- C ₆ alkyl-R ³ , -N(R ³ )-S(O) ₂ -Ci-C ₆ alkyl-R ³ , - S(O) ₂ -N(R ³ )R ^3a , -O-C ₂ -C ₆ alkyl-N(R ³ )(R ^3a ), -O-Cz-Cealkyl-OR ¹ , -S-R ³ , -S(O)-Ci-C ₆ alkyl-R ³ , -S(O) ₂ -Ci-C ₆ alkyl-R ³ , C ₃ -C ₆ cycloalkyl, heterocyclyl, C4-Cyheterocyclyl-R ³ , -O-C ₂ -C4alkyl-heterocyclyl, -O-heterocyclyl-C(O)- OR ³ , -O-C ₀ -C ₄ alkyl-aryl, -O-C ₀ -C ₄ alkyl-heteroaryl, -O-C(O)-NR ³ -C ₀ -C ₄ alkyl-aryl, -O- C(O)-NR ³ -C ₀ -C ₄ alkyl-heteroaryl, -O-C ₀ -C ₄ alkyl-heterocyclylaryl, -O-C ₀ -C ₄ alkyl- heterocyclyl-heteroaryl, -N(R ³ )-C ₂ -C ₄ alkyl-heterocyclyl, -N(R ³ )C(O)N(R ³ )-C ₀ -C ₄ alkyl- heterocyclyl-R ³ , -C ₀ -C ₄ alkyl-OC(O)-R ³ , -C ₀ -C ₄ alkyl-N(R ³ )C(O)-O-R ³ , -C ₀ -C ₄ alkyl- heterocyclyl-C(O)-O-R ³ , -N(R ³ )-C ₂ -C ₄ alkyl-heterocyclyl, F, Cl, Br, I, NO ₂ , -CF ₃ , -OCF ₃ , -OCHF ₂ , -SCF ₃ , -SF ₅₅ -SO ₃ H, -CN, -C ₁ -C ₆ alkylaryl, aryl, heteroaryl, cycloalkyl, -C ₁ -C ₆ alkylheteroaryl, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl moeity of the aformentioned R ⁴ is optionally substituted; or

selected from the group consisting of structures b-la to b-lk and (b-1) to (b-125) and Q-J-L taken together is selected from the group consisting of -C ₃ -C ₈ alkyl-, -C(O)-C ₃ - C ₈ alkyl-, -Co-C^lkyl-O-C^Csalkyl-, -Co-C^lkyl-Ci-Qalkenyl-Co-C^lkyl-, =N-0-Ci- C ₈ alkyl-, =N-O-C ₀ -C ₃ alkyl-aryl-C ₀ -C ₃ alkyl-, =N-O-C ₀ -C ₃ alkyl-aryl-C ₀ -C ₃ alkenyl-, =N- 0-Co-C ₃ alkyl-aryl-C ₀ -C ₃ alkynyl-, =N-0-Co-C ₃ alkyl-heteroaryl-C ₀ -C ₃ alkyl-, =N-0-Co- C ₃ alkyl-heteroaryl-C ₀ -C ₃ alkenyl-, =N-0-Co-C ₃ alkyl-heteroaryl-C ₀ -C ₃ alkynyl-, -C ₀ - C ₃ alkyl-aryl-C ₀ -C ₃ alkyl-, -C ₀ -C ₃ alkyl-aryl-C ₂ -C ₄ alkenyl-, -C ₀ -C ₃ alkyl-aryl-C ₂ - C ₄ alkynyl-, -Co-Csalkyl-heteroaryl-Co-Csalkyl-, -Co-Csalkyl-heteroaryl-Ci-Csalkenyl-, -Co-C ₃ alkyl-heteroaryl-Ci-C ₃ alkynyl-, -Co-C ₃ alkyl-N(R ³ )-Co-C ₃ alkyl-aryl-C _o -C ₃ alkyl-,

-Co-C3alkyl-N(R ³ )-Co-C3alkyl-aryl-C ₂ -C ₃ alkenyl-, -Co-C3alkyl-N(R ³ )-Co-C ₃ alkyl-aryl-C ₂ - C ₃ alkynyl-, -Co-C3alkyl-N(R ³ )-Co-C3alkyl-heteroaryl-Co-C ₃ alkyl-, -Co-C ₃ alkyl-N(R ³ )-C _o - C ₃ alkyl-heteroaryl-C ₂ -C ₃ alkenyl-, -Co-C ₃ alkyl-N(R ³ )-C ₀ -C ₃ alkyl-heteroaryl-C ₂ - C ₃ alkynyl-, -Co-C ₃ alkyl-C(0)-N(R ³ )-C ₀ -C ₃ alkyl-aryl-Co-C ₃ alkyl-, -Co-C ₃ alkyl-N(R ³ )- C(0)-Co-C ₃ alkyl-aryl-C ₀ -C ₃ alkyl-, -Co-C ₃ alkyl-C(0)-N(R ³ )-C ₀ -C ₃ alkyl-aryl-C ₂ - C ₃ alkenyl-, -Co-C ₃ alkyl-N(R ³ )-C(0)-C ₀ -C ₃ alkyl-aryl-C ₂ -C ₃ alkenyl-, -C ₀ -C ₃ alkyl-C(O)- N(R ³ )-C ₀ -C ₃ alkyl-aryl-C ₂ -C ₃ alkynyl-, -Co-C ₃ alkyl-N(R ³ )-C(0)-C ₀ -C ₃ alkyl-aryl-C ₂ - C ₃ alkynyl-, -Co-C ₃ alkyl-C(0)-N(R ³ )-C ₀ -C ₃ alkyl-heteroaryl-C ₀ -C ₃ alkyl-, -C _o -C ₃ alkyl- N(R ³ )-C(0)-C ₀ -C ₃ alkyl-heteroaryl-Co-C ₃ alkyl-, -Co-C ₃ alkyl-C(0)-N(R ³ )-Co-C ₃ alkyl- heteroaryl-C ₂ -C ₃ alkenyl-, -Co-C ₃ alkyl-N(R ³ )-C(0)-C ₀ -C ₃ alkyl-heteroaryl-C ₂ -C ₃ alkenyl-, -Co-C ₃ alkyl-C(0)-N(R ³ )-C ₀ -C ₃ alkyl-heteroaryl-C ₂ -C ₃ alkynyl-, -Co-C ₃ alkyl-N(R ³ )-C(0)- Co-C3alkyl-heteroaryl-C ₂ -C ₃ alkynyl-, -Co-C3alkyl-heterocyclyl-Co-C3alkyl-aryl-Co- C ₃ alkyl-, -Co-C3alkyl-C(0)-heterocyclyl-Co-C3alkyl-aryl-Co-C ₃ alkyl-, -C ₀ -C ₃ alkyl-N(R ³ )- C(0)-heterocyclyl-Co-C ₃ alkyl-aryl-Co-C ₃ alkyl-, -Co-C ₃ alkyl-0-C(0)-heterocyclyl-C ₀ - C ₃ alkyl-aryl-C ₀ -C ₃ alkyl-, -Co-C3alkyl-heterocyclyl-Co-C3alkyl-aryl-C ₂ -C ₄ alkenyl, -C ₀ - C ₃ alkyl-C(0)-heterocyclyl-Co-C ₃ alkyl-aryl-C ₂ -C ₄ alkenyl, -C ₀ -C ₃ alkyl-N(R ³ )-C(O)- heterocyclyl-C ₀ -C ₃ alkyl-aryl-C ₂ -C ₄ alkenyl, -Co-C ₃ alkyl-0-C(0)-heterocyclyl-Co-C ₃ alkyl- aryl-C ₂ -C ₄ alkenyl, -Co-C ₃ alkyl-heterocyclyl-Co-C ₃ alkyl-aryl-C ₂ -C ₄ alkynyl, -Co-C ₃ alkyl- C(O)-heterocyclyl-C ₀ -C ₃ alkyl-aryl-C ₂ -C ₄ alkynyl, -Co-C ₃ alkyl-N(R ³ )-C(0)-heterocyclyl- C ₀ -C ₃ alkyl-aryl-C ₂ -C ₄ alkynyl, -Co-C3alkyl-0-C(0)-heterocyclyl-Co-C ₃ alkyl-aryl-C ₂ - C ₄ alkynyl, -Co-C ₃ alkyl-heterocyclyl-Co-C ₃ alkyl-heteroaryl-Co-C ₃ alkyl, -Co-C ₃ alkyl-C(0)- heterocyclyl-Co-C ₃ alkyl-heteroaryl-Co-C ₃ alkyl, -Co-C ₃ alkyl-N(R ³ )-C(0)-heterocyclyl-C ₀ - C ₃ alkyl-heteroaryl-C ₀ -C ₃ alkyl, -Co-C ₃ alkyl-0-C(0)-heterocyclyl-Co-C ₃ alkyl-heteroaryl- C ₀ -C ₃ alkyl, -Co-C ₃ alkyl-heterocyclyl-Ci-C ₃ alkyl-heteroaryl-C ₂ -C ₃ alkenyl-, -C ₀ -C ₃ alkyl- C(O)-heterocyclyl-Ci-C ₃ alkyl-heteroaryl-C ₂ -C ₃ alkenyl-, -C ₀ -C ₃ alkyl-N(R ³ )-C(O)- heterocyclyl-Ci-C ₃ alkyl-heteroaryl-C ₂ -C ₃ alkenyl-, -C ₀ -C ₃ alkyl-O-C(O)-heterocyclyl-Ci- C3alkyl-heteroaryl-C ₂ -C3alkenyl-, -Co-C3alkyl-heterocyclyl-Ci-C3alkyl-heteroaryl-C ₂ - C ₃ alkynyl-, -Co-C ₃ alkyl-C(0)-heterocyclyl-Ci-C3alkyl-heteroaryl-C ₂ -C ₃ alkynyl-, -C ₀ - C ₃ alkyl-N(R ³ )-C(O)-heterocyclyl-Ci-C ₃ alkyl-heteroaryl-C ₂ -C ₃ alkynyl-, -Co-C ₃ alkyl-0- C(O)-heterocyclyl-Ci-C ₃ alkyl-heteroaryl-C ₂ -C ₃ alkynyl-, -C ₂ -C ₄ alkyl-O-C ₀ -C ₃ alkyl-aryl-, -C ₂ -C ₄ alkyl-0-Co-C ₃ alkyl-aryl-Co-C ₃ alkyl-, -C ₂ -C ₄ alkyl-O-C ₀ -C ₃ alkyl-aryl-C ₂ -C ₄ alkenyl, -C ₂ -C ₄ alkyl-O-C ₀ -C ₃ alkyl-aryl-C ₂ -C ₄ alkynyl, -C ₂ -C ₄ alkyl-0-C ₀ -C ₃ alkyl-heteroaryl-Co- C ₃ alkyl, -C ₂ -C ₄ alkyl-O-Ci-C ₃ alkyl-heteroaryl-C ₂ -C ₃ alkenyl-, -C ₂ -C ₄ alkyl-O-Ci-C ₃ alkyl- heteroaryl-C ₂ -C ₃ alkynyl-,

-Co-Cealkyl-U-bridged heterocyclyl-heteroaryl-Co-Cealkyl-,

-Co-C ₆ alkyl-U-bridged heterocyclyl-N(R ³ )-heteroaryl-Co-C ₆ alkyl-,

-Co-C ₆ alkyl-U-N(R ³ )-bridged heterocyclyl-heteroaryl-Co-C ₆ alkyl-,

-Co-Cealkyl-U-bridged heterocyclyl-aryl-Co-Cealkyl-,

-Co-C ₆ alkyl-U-bridged heterocyclyl-N(R ³ )-aryl-Co-C ₆ alkyl-,

-Co-C ₆ alkyl-U-N(R ³ )-bridged heterocyclyl-aryl-Co-C ₆ alkyl-,

-Co-C ₆ alkyl-U-bridged heterocyclyl-aryl-C ₂ -C ₆ alkenyl-,

-Co-C ₆ alkyl-U-bridged heterocyclyl-N(R ³ )-aryl-C ₂ -C ₆ alkenyl-,

-Co-C ₆ alkyl-U-N(R ³ )-bridged heterocyclyl-aryl-C ₂ -C ₆ alkenyl-,

-Co-C ₆ alkyl-U-bridged heterocyclyl-heteroaryl-C ₂ -C ₆ alkenyl-,

-Co-C ₆ alkyl-U-bridged heterocyclyl-N(R ³ )-heteroaryl-C ₂ -C ₆ alkenyl-,

-Co-C ₆ alkyl-U-N(R ³ )-bridged heterocyclyl-heteroaryl-C ₂ -C ₆ alkenyl-,

-Co-Cealkyl-bridged heterocyclyl-U-heteroaryl-Co-Cealkyl-,

-Co-C ₆ alkyl-N(R ³ )-bridged heterocyclyl-U-heteroaryl-Co-C ₆ alkyl-,

-Co-C ₆ alkyl-bridged heterocyclyl-N(R ³ )-U-heteroaryl-Co-C ₆ alkyl-,

-Co-Cealkyl-bridged heterocyclyl-U-aryl-Co-Cealkyl-,

-Co-C ₆ alkyl-N(R ³ )-bridged heterocyclyl-U-aryl-Co-C ₆ alkyl-,

-Co-C ₆ alkyl-bridged heterocyclyl-N(R ³ )-U-aryl-Co-C ₆ alkyl-,

-Co-C ₆ alkyl-bridged heterocyclyl-U-aryl-C ₂ -C ₆ alkenyl-,

-Co-C ₆ alkyl-N(R ³ )-bridged heterocyclyl-U-aryl-C ₂ -C ₆ alkenyl-,

-Co-C ₆ alkyl-bridged heterocyclyl-N(R ³ )-U-aryl-C ₂ -C ₆ alkenyl-,

-Co-C ₆ alkyl-bridged heterocyclyl-U-heteroaryl-C ₂ -C ₆ alkenyl-,

-Co-C ₆ alkyl-N(R )-bridged heterocyclyl-U-heteroaryl-C ₂ -C ₆ alkenyl-, and

-Co-C ₆ alkyl-bridged heterocyclyl-N(R ³ )-U-heteroaryl-C ₂ -C ₆ alkenyl-, wherein each alkyl, alkenyl, aryl, alkynyl, heteroaryl and heterocyclyl moiety is optionally substituted; and wherein the bridge is methylene or propylene; provided that Formula (I) excludes those compounds wherein

-Q-J-L-C(O)Z is optionally substituted -Ci-Ci ₃ alkyl-N(R ³ )-C ₀ -C ₆ alkyl-aryl-C ₂ alkenyl- C(O)NHOH; and

is selected from the group consisting of aromatic polycycles, non-aromatic polycycles, mixed aryl and non-arylpolycycles, polyheteroaryl, non-aromatic

polyheterocycles, and mixed aryl and non-aryl polyheterocycles, each of which is optionally substituted; and provided that Formula (I) excludes compounds of Formula (A)

wherein R , 906 is selected from the group consisting of aryl and heteroaryl;

T ⁹⁰⁶ is selected from the group consisting of -Co-6alkyl-S(0)2-Co-6alkyl-, -Co-6alkyl-C(0)-Co- ₆ alkyl- andC^alkyl, wherein T ⁹⁰⁶ is substituted at the carbon atom attached to R ⁹⁰⁶ with a moiety selected from the group consisting of;aryl, heteroaryl, cycloalkyl and heterocycle;

A ⁹⁰⁶ is an optionally substituted unbridged heterocycle; Q ⁹⁰⁶ is a bond;

Het is an optionally substituted 5-membered aryl ring; L ⁹⁰⁶ is a bond or -Ci_ ₄ alkyl-; and

R ^906a is -N(R ^906b )OH, wherein R ^906b is selected from the group consisting of H, optionally substituted alkyl and optionally substituted aryl; and provided that Formula (I) excludes those compounds wherein

-Q-J-L-C(O)Z is optionally substituted -CQ-Qalkyl-X-Ci-Qalkyl-phenyl-C^lkenyl-

C(O)NHOH;

is a 5- or 6-membered aromatic heterocyclic group condensed with a carbon ring or

other heterocyclic ring, which is substituted with 1 to 4 substituents selected from phenyl, another 5- or 6-membered aromatic heterocyclic group and a heterocyclic group, said heterocyclic group being optionally substituted with Ci_4alkyl, a benzyl group or a pyridylmethyl group; and

X is a moiety having a structure selected from the group consisting of -C(O)N(R ,AK )-, -O- C C((00))--NN((RR ^AA11 ))__,, --SSOO ₂₂ --,, --NN((RR^^))SSOO ₂₂ --, wherein R ^A1 and R ^A2 are independently -H or optionally substituted Ci-C ₄ alkyl;

and provided that Formula (I) excludes compounds wherein B-Q- is

-J-L- is , wherein R is directly attached or attached through a linker, and is selected from the group consisting of substituted or unsubstituted aryl, cycloalkyl, cycloalkylamino, naphtha, pyridineamino, piperidino, 9-purine-6-amine, thiazoleamino group, hydroxyl, branched or unbranched alkyl, alkenyl, alkyoxy, aryloxy, arylalkyloxy and pyridine group, wherein the linker is selected from the group consisting of an amide moiety, -O-, -S-, -NH- and -CH ₂ -; and provided that Formula (I) excludes compounds of Formula (B)

wherein R ^B is H or phenyl;

A ^B is a bi- or tricyclic residue optionally partially or totally unsaturated, and which optionally contains one or more heteroatoms selected from the group consisting of N, S and O, and optionally substituted by hydroxy, alkanoyloxy, primary, secondary or tertiary amino, aminoCi-C ₄ alkyl, mono- or di(Ci-C ₄ )alkyl-aminoCi-C ₄ alkyl, halogen, Ci-C ₄ alkyl and tri(Ci-C ₄ )alkylammoniumCi-C ₄ alkyl; is a chain of 1 to 5 carbon atoms optionally containing a double bond or an NR group, wherein R is H or Ci-C ₄ alkyl;

X ^B is absent, an oxygen atom or an NR group, wherein R is H or Ci-C ₄ alkyl; and

B ^B is a phenylene or cyclohexylene ring; and provided that Formula (I) excludes compounds of Formula (D)

wherein

A ^D is selected from the group consisting of a 4- to 10-membered aromatic or non-aromatic heterocyclyl;

X ^D is C=O or S(O) ₂ ; R ^D1 is H or Ci-Cealkyl;

R ^D2 is independently selected from the group consisting of oxo, (C=O)-NH ₂ , Ci-C ₆ alkyl-aryl and heterocyclyl, when A ^D is a non-aromatic heterocycle, wherein said alkyl, and aryl moieties are optionally substituted with one to three R ^b ; or

R ^D2 is independently selected from the group consisting of OH, NO ₂ , (C=O) _0-1 -O _0-1 -C ₁ -

C ₆ alkyl, CN, (C=0)o.i-Oo.i-C ₃ -C ₁₀ cycloakyl, halogen, (C=O) ₀ _i-N(R ^a ) ₂ , CF ₃ , NH-S(O) _0-2 - R ^a , (C=0)o-i-Oo-i-heterocyclyl, (C=O) ₀ -i-O ₀ -i-aryl, S(O) ₀ - ₂ -R ^a , NH(C=0)R ^a , Ci-C ₆ alkyl- aryl and heterocyclyl, when A ^D is an aromatic heterocyclyl, wherein said alkyl, cycloalkyl, aryl and heterocyclyl are optionally substituted with one to three R ^b ;

R ^a is independently H or d-C ₆ alkyl; and

R ^b is independently selected from the group consisting of oxo, NO ₂ , N(R ^a ) ₂ , OH, CN, halogen, CF ₃ and Ci-Cβalkyl; and provided that Formula (I) excludes compounds of Formula (E)

wherein

A ^E is selected from the group consisting Of -CH ₂ -O-, -CH ₂ -S-, -CH ₂ -CH ₂ - and -NH-CO-; X ^E is selected from the group consisting of -N(R ^E3 )-, =C(0) and -CH(OH)-; Y ^E is selected from the group consisting of O, S and -N(R ^E4 )-;

Z ^E is selected from the group consisting of a straight chain C4-C8alkylene, wherein one CH ₂ group may be replaced by an oxygen or a sulfur atom, or wherein 2 carbon atoms form a C=C double bond, and which is either unsubstituted or substituted by one or two substituents selected from d-C ₄ alkyl and halogen;

R ^E1 and R ^E2 are independently selected from the group consisting of H, halogen, Ci-C ₄ alkyl, trifluoromethyl, hydroxy, Ci-C4alkoxy, benzyloxy, Ci-C3alkylenedioxy, nitro, amino, Ci- C4alkylamino, di[(Ci-C4)alkyl]-amino, and Ci-C4alkanoylamino; and

R ^E3 and R ^E4 are independently selected from H and Ci-C ₄ alkyl; and provided that Formula (I) excludes compounds of Formula (F) A ^F -Q ^1F -J ^F -Q ^2F -C(O)-NH-OH (F) wherein

A ^F is a C ₅ -C ₂₀ aryl group or a 5-20 membered heteroaryl group, each having one ring or two or more fused rings, wherein at least one ring is aromatic, said ary and heteroaryl groups being optionally substituted;

Q ^1F is a linker group having a backbone length of at least 2 carbon atoms, the linker being optionally substituted;

J ^F is -N(R ^F )-C(O)- or -C(O)-N(R ^F )-;

Q ^2F is selected from the group consisting of Ci-Cioalkyl, Cs-C2oaryl, 5 to 20 membered heteroaryl, C ₅ -C ₂ oaryl-Ci-Cioalkyl, 5 to 20 membered heteroaryl-Ci-Cioalkyl, Ci- Cioalkyl-C ₅ -C ₂ oaryl and Ci-Cioalkyl-5 to 20 membered heteroaryl, each of which is optionally substituted; and

R ^F is selected from the group consisting of H, Ci-Cyalkyl, C3-C2oheterocyclyl and Cs-C2oaryl, each of which is optionally substituted; and provided that Formula (I) excludes compounds wherein Z is -N(R ¹ XOR ² );

R ¹ and R ² are independently selected from the group consisting of H, Ci-Cβalkyl, aryl and heteroaryl;

L is a bond; and

is selected from the group consisting of hydrogen, aryl, aryl-alkyl-, heteroaryl, heteroaryl-alkyl-, heterocyclyl, cycloalkyl, heterocyclyl-alkyl, cycloalkyl-alkyl, C ₁ - Cioalkyl, (aryl) ₂ -CH-C ₀ -C ₆ alkyl-, (aryl)(heteroaryl)CH-C ₀ -C ₆ alkyl- and (heteroaryl) ₂ CH- Co-Cβalkyl-, each of which is optionally substituted; and

Q comprises a ring selected from the group consisting o f

, wherein Y^ is nitrogen or -CH<, and Z^ is oxygen,

NH or -CH ₂ - if Z ^F is not bonded to , or Z^ is nitrogen or -CH< if Z^ is bonded to

or

is selected from the group consisting of b-53, b-62 (wherein D ³ is or

), b-69 (wherein R ⁴ is H), b-70, b-72 (wherein D ³ is \ b-92 and b-93; and

Q-J is selected from the group consisting of -X ^F -Co- ₄ alkyl-aryl-Co- ₄ alkyl-, -X ^F -Co- ₄ alkyl- heteroaryl-Co- ₄ alkyl-, and -X ^F -Co- ₄ alkyl-heterocyclyl-Co_ ₄ alkyl-, wherein said alkyl, aryl, heteroaryl, and heterocyclyl are optionally substituted, and wherein said hetercyclyl is a mono- or bi-saturated or mono- or bi-unsaturated heterocyclic ring, and wherein

X ^F is selected from the group consisting of

O

wherein the left side attaches to , and wherein r and s are each independently 0, 1 , 2, 3, 4 or 5, wherein r and s cannot be both 0 and when r or s are 0 then a direct bound in intended; each r' is independently 0, 1, 3, 3 or 4 and r' cannot be 0 when s is 0; R ^4A is H, Ci_ ₆ alkyl or phenyl; Y ^F is nitrogen or -CH<, and Z ^F is oxygen, NH or -CH ₂ - if Z ^F is not

_{F F} ( B bonded to or Z is nitrogen or -CH< if Z is bonded to ^-^ .; and provided that Formula (I) excludes those compounds having the following structure:

^R , wherein

X ⁹ is selected from the group consisting of CO, SO ₂ and CH ₂ ;

Y ⁹ is selected from the group consisting of N-R ^9f , CH-OR ^9f , CH-NR ^9f R ⁹¹ and C=CH-CO-R ^9g ;

A ⁹ and B ⁹ are independently selected from 5- or 6-membered rings;

R ^9a , R ^9b , R ^9c and R ^9d are independently selected from the group consisting of H, halogen, CF ₃ , NO ₂ , NR ^9l R ^9j , CN, COOH, (CH ₂ ) ₀ - ₂ -CONR ^9l R ^9j , C _1-6 alkyl, OH, O-C _1-6 alkyl, O- cyclopropyl, O-(CH ₂ ) ₂ -O-Ci. ₆ alkyl, O-(CH ₂ ) ₂ -NR ^9l R ^9j , 0-CONHR ⁹¹ , CH ₂ -Z ⁹ -R ^9h , COR ⁹¹ , CR ^9l R ^9m R ⁹ⁿ , SR ⁹¹ , SO ₂ R ⁹⁰ , CR ⁹¹ NOR ⁹¹ , CR ⁹¹ NNR ⁹¹ R ⁹ J, a Q ⁹ -(CH ₂ ) ₂ . ₉ CONHOH group, furan, thiophene, pyrrole, oxazole, thiazole, imidazole, pyrazole, isoxazole, isothiazole, 1,2,3-oxathiazole, 1,2,3-triazole, pyridine, pyridazine, pyrimidine, pyrazine, morpholine thiomorpholine, piperidine and pyrrolidine;

R ^9e and R ^9f are Q ^9a -(CH ₂ ) ₂ . ₉ CONHOH;

R ^9g is NH-(CH ₂ ) ₂ . ₉ CONHOH;

R ^9h is a (CH ₂ )P-R ^9k group, wherein R ^9k can be methyl or hydroxyl;

Z ⁹ is selected from the group consisting of O, NR ^9L and S;

Q ⁹ is selected from the group consisting of a chemical bond, -O-, -S-, -NR ^9L -, -NR ⁹¹ CO-, -CONR ⁹¹ -, -W ⁹ -, -COW ⁹ -, wherein W ⁹ is piperidine or pyrrolidine;

Q ^9a is a bond or a -CO-;

R ⁹¹ and R ^9j are independently H or a Ci_ ₆ alkyl;

R ^9L is H or R ^9h ;

R ^9m and R ⁹ⁿ can either be a fluorine atom or oxygen atoms linked together by an alkyl chain consisting of 2 or 3 CH ₂ ; and R ⁹ ° is a Ci_ ₆ alkyl; provided that (1) only one (CH ₂ ) ₂ - ₉ CONHOH is present in the molecule and (2) when X ⁹ is CO and A ⁹ and B ⁹ are both benzene then R ^9c and R ^9d cannot signify

Q ⁹ -(CH ₂ ) ₂ - ₉ CONHOH.

2. The compound according to claim 1, wherein Q comprises a bridged heterocycle,

comprises a first ring structure, said first ring structure attached via a covalent bond to said bridged heterocycle and J comprises a second ring structure, said second ring structure attached via a covalent bond to said bridged heterocycle, each of which is optionally substituted. In another preferred embodiment, L is a covalent bond.

3. The compound according to claim 1 or claim 2, wherein is a radical selected from the group consisting of

4. The compound according to any of claims 1 to 3, wherein a radical selected from the group consisting of

wherein when

is attached via , and wherein when ,Qis attached via D^D ² .

5. The compound according to any of claims 1 to 4, wherein is a radical selected from the group consisting of

6. The compound according to any of claims 1 to 5, wherein Q is an optionally substituted moiety selected from the group consisting of

or where possible, an (R,R) or (S, S) enantiomer or a mixture of enantiomers, preferably an (R,R) enantiomer, more preferably an (S, S) enantiomer thereof, wherein G and G ¹ are independently selected from -CH- and N; wl and w2 are independently 0, 1, 2 or 3, provided that when both G and G ¹ are N, then wl and W2 are independently 1, 2 or 3; and wherein each ring structure includes a 0 (i.e., a bond), 1, 2 or 3 carbon bridge

between two non-adjacent carbon atoms, provided that is absent when U is H, N(R ³ )(R ^3a )-C ₂ -C ₄ alkyl- or R ³ -O-C ₂ -C ₄ alkyl-. Preferrably the ring size is 6, 7, 8 or 9 ring atoms, excluding any bridge atoms.

7. The compound according to any of claims 1 to 6, wherein Q is an optionally substituted moiety selected from the group consisting of

or where possible, an (R,R) or (S, S) enantiomer or a mixture of enantiomers, preferably an (R,R) enantiomer, more preferably an (S, S) enantiomer thereof, wherein wl and w2 are independently 0, 1, 2 or 3, provided that when the ring includes two N atoms, then wl and w2 are independently 1, 2 or 3; and wherein each ring structure includes a 0 (i.e., a bond), 1, 2 or 3 carbon bridge between two non-adjacent carbon atoms, provided that

absent when U ¹ is H, N(R ³ )(R ^3a )-C ₂ -C ₄ alkyl- or R ³ -O-C ₂ -C ₄ alkyl-.

8. The compound according to any of claims 1 to 5, wherein Q is an optionally substituted moiety, selected from the group consisting of

-

or wherein possible, a (R,R) or (S, S) enantiomer or a mixture of enantiomers, preferably an (R,R) enantiomer, more preferably an (S, S) enantiomer thereof, wherein n is 1, 2 or 3,

and wherein K is absent when Q is structure (a-1), (a-2), (a-3) or when U is H, N(R ³ )(R ^3a )-C ₂ -C ₄ alkyl- or R ³ -O-C ₂ -C ₄ alkyl-.

9. The compound according to any of claims 1 to 5, wherein Q is an optionally substituted moiety selected from the group consisting of

or wherein possible, a (R,R) or (S, S) enantiomer or a mixture of enantiomers, preferably an

(R,R) enantiomer, more preferably an (S, S) enantiomer thereof, where 3iinn r iss absent when U ¹ is H, N(R ³ )(R ^3a )-C ₂ -C ₄ alkyl- or R ³ -O-C ₂ -C ₄ alkyl-.

10. The compound according to claim 1, wherein

Z is -N(R ¹ XOR ² );

L is a covalent bond;

J is selected from the group consisting of a covalent bond, =CH-, -Ci-Cgalkyl-, -Co-C ₃ alkyl- Ci-C ₈ heteroalkyl-Co-C ₃ alkyl-, -Co-Csalkyl-Cz-Csalkenyl-Co-Csalkyl-, -C ₀ -C ₃ alkyl-C ₂ - C ₈ alkynyl-Co-C ₃ alkyl-, -Co-Cealkyl-aryl-Co-Cealkyl-, -Co-Cealkyl-aryl-Cz-Ceheteroalkyl-, -Co-Cealkyl-cycloalkyl-Co-Cβalkyl-, ^-Ceheterocyclyl-aryl-Co-Cealkyl-, -C ₄ - Ceheterocyclyl-aryl-Co-Ceheteroalkyl-, -Co-C ₆ alkyl-C ₄ -C ₆ heterocyclyl-Co-Cealkyl-, -Co- C ₆ alkyl-heteroaryl-Co-C ₆ alkyl-, -Co-Cealkyl-heteroaryl-Co-Cβheteroalkyl-, -C ₄ - Ceheterocyclyl-heteroaryl-Co-Cealkyl-, -Co-C ₆ alkyl-aryl-C ₂ -Cealkynyl-, -Co-Cβalkyl- heteroaryl-C ₂ -C ₆ alkynyl-, -Co-C ₆ alkyl-aryl-C ₂ -C ₆ alkynyl-C ₂ -C ₆ alkenyl-, -Co-Cealkyl-aryl- C ₂ -C ₆ alkenyl-, -C ₀ -C ₆ alkyl-heteroaryl-C ₂ -C ₆ alkenyl-, -C ₂ -C ₆ alkenyl-aryl-C ₀ -C ₆ alkyl-, -C ₂ -C ₆ alkenyl-heteroaryl-C ₀ -C ₆ alkyl-, -Co-Cealkylaryl-aryl-Co-Cealkyl-, -C ₀ -C ₆ alkylaryl- heteroaryl-Co-C ₆ alkyl- and -Co-Cealkyl-Cs-Cecycloalkyl-Co-Cβalkyl-, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, aryl, heteroaryl, heterocyclyl, and cycloalkyl moiety is optionally substituted, wherein when J is =CH-, Q is a covalent bond and B is attached through a carbon sp ² to J;

Q is a moiety selected from the group consisting of

or an optionally substituted (R,R) or (S, S) enantiomer or a mixture of enantiomers, preferably an (R,R) enantiomer, more preferably an (S, S) enantiomer thereof, wherein n is 0, 1, 2 or 3; and

U is selected from the group consisting of -Co-C ₈ alkyl-C(0)-Co-C ₃ alkyl-, -Ci-Cgalkyl-, -Co- C ₈ alkyl-N(R ³ )-C(O)-C ₀ -C ₃ alkyl-, -C ₀ -C ₈ alkyl-0-C(0)-Co-C ₃ alkyl-, -Co-C ₈ alkyl-N(R ³ )- C(S)-Co-C ₃ alkyl-, -Co-C ₈ alkyl-0-C(S)-Co-C ₃ alkyl-, -Co-C ₈ alkyl-N(R ³ )-S(0) ₂ -Co-C ₃ alkyl-, -Co-Cgalkyl-heterocyclyl-Co-Csalkyl-, a covalent bond and -O-C ₂ -C ₄ alkyl-; and

U ¹ is selected from the group consisting of H, -Co-C ₈ alkyl-C(0)-Co-C ₃ alkyl-, -Ci-Cgalkyl-, -Co-C ₈ alkyl-N(R ³ )-C(0)-C ₀ -C ₃ alkyl-, -C ₀ -C ₈ alkyl-O-C(O)-C ₀ -C ₃ alkyl-, -C ₀ -C ₈ alkyl- N(R ³ )-C(S)-C ₀ -C ₃ alkyl-, -Co-C ₈ alkyl-0-C(S)-C ₀ -C ₃ alkyl-, -Co-C ₈ alkyl-N(R ³ )-S(0) ₂ -C ₀ - C ₃ alkyl-, -Co-Csalkyl-heterocyclyl-Co-Csalkyl-, a covalent bond, (R ³ )(R ^3a )N-C ₂ -C ₄ alkyl-, -O-C ₂ -C ₄ alkyl-, and R ³ -O-C ₂ -C ₄ alkyl-;

wherein is absent when Q is structure (a-1), (a-2), (a-3) or when U i is H,

N(R ³ )(R ^3a )-C ₂ -C ₄ alkyl- or R ³ -O-C ₂ -C ₄ alkyl-.

11. The compound according to any of claim 10, wherein J is selected from the group consisting of a -Co-Csalkyl-Ci-Csheteroalkyl-Co-Csalkyl-, -Co-Cealkyl-aryl-Co-Cβalkyl-, -Co-

C ₆ alkyl-aryl-C ₂ -C ₆ heteroalkyl-, -Co-Cealkyl-cycloalkyl-Co-Cβalkyl-, -C-rCeheterocyclyl-aryl- Co-Cβalkyl-, -C4-C6heterocyclyl-aryl-Co-C6heteroalkyl-, -Co-Cβalkyl-C-rCeheterocyclyl-Co- C ₆ alkyl-, -Co-Cealkyl-heteroaryl-Co-Cealkyl-, -Co-Cealkyl-heteroaryl-Co-Ceheteroalkyl-, -C ₄ - C ₆ heterocyclyl-heteroaryl-Co-C ₆ alkyl-, -Co-C ₆ alkyl-aryl-C ₂ -C ₆ alkynyl-, -C ₀ -C ₆ alkyl- heteroaryl-C2-C6alkynyl-, -Co-C6alkyl-aryl-C2-C6alkynyl-C2-C6alkenyl-, -Co-Cealkyl-aryl-C2- Cβalkenyl-, -Co-Cealkyl-heteroaryl^-Cealkenyl-, -C ₂ -C ₆ alkenyl-aryl-Co-C ₆ alkyl-, -C ₂ - Cealkenyl-heteroaryl-Co-Cealkyl-, -Co-Cealkylaryl-aryl-Co-Cβalkyl-, -Co-Cβalkylaryl- heteroaryl-Co-Cealkyl- and -Co-Cealkyl-Cs-Cecycloalkyl-Co-Cβalkyl-, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, aryl, heteroaryl, heterocyclyl, and cycloalkyl moiety is optionally substituted.

12. The compound according to claim 11, wherein J is -Co-Cealkyl-heteroaryl-Co-Cealkyl- or -Co-Cealkyl-aryl-Co-Cealkyl-.

13. The compound according to any of claims 10 to 12, wherein Q is selected from the group consisting of

14. The compound according to any of claims 10 to 13, wherein U and U ¹ are a covalent bond.

15. The compound according to any of claims 10 to 13, wherein U and U ¹ are -C(O)-.

16. The compound according to any of claims 10 to 13, wherein U is -C(O)-O-Co- C ₃ alkyl-.

17. The compound according to any of claims 10 to 13, wherein U ¹ is -Co-Csalkyl-O- C(O)-.

18. The compound according to claim 1, wherein

J is selected from the group consisting of -Ci-Cgalkyl-, -Co-Cealkyl-aryl-Co-Csalkyl- C ₂ alkenyl-Co-C ₃ alkyl, -Co-Cealkyl-heteroaryl-Co-Csalkyl-Czalkenyl-Co-Csalkyl, -C ₀ - C ₆ alkyl-aryl-C ₀ -C ₆ alkyl- and -Co-Cealkyl-heteroaryl-Co-Cβalkyl-, wherein each is optionally substituted;

Q is selected from the group consisting of a covalent bond, -Ci-Cgalkyl-, =N-O-, -Co-Cβalkyl- N(R ³ )-C ₀ -C ₃ alkyl-, -Co-Cealkyl-heterocyclyl-Co-Csalkyl-, -Co-C ₆ alkyl-C(0)-Co-C ₃ alkyl-, -Co-C6alkyl-0-Co-C3alkyl-, -Co-C6alkyl-(CR ³ =CR ³ )i. ₂ -Co-C6alkyl-, -Co-C ₆ alkyl-(C≡C)i, C ₀ -C ₆ alkyl-, -C ₀ -C ₆ alkyl-N(R ³ )-C(0)-Co-C ₃ alkyl-,wherein each alkyl and heterocyclyl moiety is optionally substituted; or

Q is selected from the group consisting of:

, wherein

U ¹ is selected from the group consisting of -Co-C ₈ alkyl-C(0)-Co-C ₃ alkyl-, -Ci-Cgalkyl-, -C ₀ - C ₈ alkyl-O-C(O)-C ₀ -C ₃ alkyl- and a covalent bond; wherein, when B is attached to Q via a N in B, then Q is selected from the group consisting of a covalent bond, -C(O)-Ci-C ₃ alkyl-O-, -Ci-C ₈ alkyl-, -Co-C ₆ alkyl-C(0)-Co-C ₃ alkyl-, -C ₂ - C ₆ alkyl-O-C ₀ -C ₃ alkyl-, -Ci-C ₆ alkyl-(CR ³ =CR ³ )i_ ₂ -C ₀ -C ₆ alkyl- and -Ci-C ₆ alkyl-(C≡C)i_ ₂ - Co-Cβalkyl-, wherein each alkyl moiety is optionally substituted;

selected from the group consisting of hydrogen, aryl, cycloalkyl, heterocyclyl, heteroaryl, heteroarylalkyl, aryl-alkyl-, (heteroaryl) ₂ -CH-Co-Cealkyl- and (aryl) ₂ -CH-Co-

Cβalkyl-, each of which is optionally substituted, provided that Q is or

a radical selected from the group consisting of

19. The compound according to claim 18, wherein IS

20. The compound according to claim 1, wherein the compound has a structure selected from the group consisting of

21. The compound according to any of claims 1 to 9, wherein Z is -NR ¹ OR ² , R ¹ and R ² are H, and L is a covalent bond.

22. The compound according to any of claims 1 to 9, wherein Z is H and L is -N(OH).

23. The compound according to any of claims 1 to 9, wherein J is selected from the group consisting of -Ci-C ₈ alkyl-, -Co-Csalkyl-Ci-Csalkenyl-Co-Cs-alkyl, -Co-C ₆ alkyl-aryl-Co- C ₆ alkyl-, -C ₀ -C ₆ alkyl-aryl-C ₂ -C ₆ alkenyl, -Co-Cealkyl-heteroaryl-Co-Cealkyl- and -C ₀ -C ₆ alkyl- heterocyclyl-heteroaryl-Co-C ₆ alkyl-.

24. The compound according to any of claims 1 to 9, wherein J is selected from the group consisting of

25. The compound according to any of claims 1 to 5, wherein Q is selected from the group consisting of a covalent bond, -Ci-Cgalkyl-, =N-O-, -Co-C ₆ alkyl-N(R ³ )-Co-C ₃ alkyl-, -Co-Cealkyl-heterocyclyl-Co-Csalkyl-, -Co-C ₆ alkyl-C(0)-Co-C ₃ alkyl-, -Co-C ₆ alkyl-0-C ₀ - C ₃ alkyl-, -Co-C ₆ alkyl-(CR ³ =CR ³ )i_ ₂ -Co-C ₆ alkyl-, -C ₀ -C ₆ alkyl-(C≡C)i. ₂ -C ₀ -C ₆ alkyl-, -C ₀ - C ₆ alkyl-N(R ³ )-C(0)-Co-C ₃ alkyl-, -Co-C ₆ alkyl-N(R ³ )-C(0)-alkenyl-Co-C ₄ alkyl-, -Co-C ₆ alkyl- C(O)-N(R ³ )-C ₀ -C ₄ alkyl-, -Co-C ₆ alkyl-S0 ₂ -N(R ³ )-C ₀ -C ₃ alkyl-, -Co-C ₆ alkyl-N(R ³ )-S0 ₂ -C ₀ - C ₃ alkyl-, -Co-C ₃ alkyl-N(R ³ )-S(0) ₂ -N(R ³ )-C ₀ -C ₃ alkyl-, -Co-C ₆ alkyl-S-Co-C ₃ alkyl-, -C ₀ - C ₆ alkyl-S(O)-C ₀ -C ₃ alkyl-, -Co-C ₆ alkyl-S(0) ₂ -C ₀ -C ₃ alkyl-, -Co-C ₆ alkyl-N(R ³ )-C(0)-N(R ³ )- C ₀ -C ₃ alkyl-, -Co-C ₃ alkyl-C=N-0-Co-C ₃ alkyl-, -heterocyclyl-Co-Csalkyl-heterocyclyl-Co- C ₃ alkyl-, -S02-Co-C6alkyl-heterocyclyl-Co-C ₃ alkyl-, -C(O)-C ₀ -C ₆ alkyl-bridged heterocyclyl- Co-C ₃ alkyl-, -N(R ³ )-C(0)-C ₀ -C ₆ alkyl-heterocyclyl-Co-C ₃ alkyl-, -0-C(0)-Co-C ₆ alkyl- heterocyclyl-Co-C ₃ alkyl-, -N(R ³ )-C(S)-C ₀ -C ₆ alkyl-heterocyclyl-C ₀ -C ₃ alkyl-, -0-C(S)-C ₀ - C ₆ alkyl-heterocyclyl-C ₀ -C ₃ alkyl-, -N(R ³ )-S(0) ₂ -Co-C6alkyl-heterocyclyl-Co-C ₃ alkyl-, -C ₀ - C ₆ alkyl-heterocyclyl-Co-C ₃ alkyl-Sθ2-N(R ³ )-, -C ₀ -C ₆ alkyl-heterocyclyl-Co-C ₃ alkyl-C(0)-

N(R ³ )- and -Co-C6alkyl-heterocyclyl-Co-C3alkyl-C(0)-0-, wherein each alkyl, heterocyclyl and alkenyl moiety is optionally substituted.

26. The compound according to any of claims 1 to 5, wherein Q is selected from the group consisting of covalent bond, =N-O-, -Ci-Cg alkyl-, -Co-C ₆ alkyl-N(R3)-Co-C3 alkyl-, -C ₀ -C ₆ alkyl-C(0)-Co-C ₃ alkyl-, -C ₀ -C ₆ alkyl-C(0)NR ₃ -Co-C ₃ alkyl-, -C ₀ -C ₆ alkyl-O-C ₀ -C ₃ alkyl- and -C ₀ -C ₃ alkyl- heterocyclyl-C ₀ -C ₃ -alkyl.

27. The compound according to any of claims 1 to 5, wherein Q is selected from the group consisting of

28. The compound according to claim 1, wherein is selected from the group consisting of aryl, aryl-alkyl-, heteroaryl, heteroaryl-alkyl-, (aryl) ₂ -CH-C ₀ -C ₆ alkyl-, (aryl)(heteroaryl)CH-C ₀ -C ₆ alkyl-, (heteroaryl) ₂ CH-C ₀ -C ₆ alkyl- and (aryl) ₂ -CH-C ₀ -C ₆ alkyl- C(O)-, -wherein each group is optionally substituted with 1, 2, 3 or 4 substituents independently selected from the group consisting of hydroxy, amino, halo, Ci-C ₆ alkyl, nitro, cyano, C ₂ -C ₆ alkoxy, Ci-C ₆ alkylamino and CF ₃ .

29. The compound according to claim 1, wherein selected from the group consisting of

30. The compound according to any of claims 1 to 29, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, aryl, heteroaryl, heterocyclyl, and cycloalkyl moiety of J is optionally substituted with from one to three substituents independently selected from the group consisting of alkyl, heterocyclyl, C ₂ -C ₆ alkenyl, C ₂ -C ₃ alkynyl, C ₂ -C ₄ alkyl-OR ¹ , heteroalkyl, heteroaryl, C ₀ -C ₆ alkylheteroaryl, C(O)CF ₃ , -C(O)-NH ₂ , -Cs-Cecycloalkyl, -alkyl-C ₃ - Cβcycloalkyl, -Ci-Cβalkylaryl, aryl, alkylheteroaryl and heteroaryl.

31. The compound according to any of claims 1 to 5, wherein Q is selected from the group consisting of a covalent bond, -Ci-Csalkyl-, =N-O-, -Co-Cealkyl-N(R )-Co-C ₃ alkyl-, -Co-Cealkyl-heterocyclyl-Co-Csalkyl-, -Co-C ₆ alkyl-C(0)-C ₀ -C ₃ alkyl-, -Co-C ₆ alkyl-0-C ₀ - C ₃ alkyl-, -Co-C ₆ alkyl-(CR ³ =CR ³ )i_ ₂ -Co-C ₆ alkyl-, -Co-C ₆ alkyl-(C≡C)i_ ₂ -Co-C ₆ alkyl-, -C ₀ - C ₆ alkyl-N(R ³ )-C(O)-C ₀ -C ₃ alkyl-, -C ₀ -C ₆ alkyl-N(R ³ )-C(0)-alkenyl-Co-C ₄ alkyl-, -Co-C ₆ alkyl-

C(O)-N(R ³ )-C ₀ -C ₄ alkyl-, -Co-C6alkyl-S0 ₂ -N(R ³ )-Co-C ₃ alkyl-, -Co-C ₆ alkyl-N(R ³ )-S0 ₂ -C ₀ - C ₃ alkyl-, -C ₀ -C3alkyl-N(R ³ )-S(0) ₂ -N(R ³ )-Co-C ₃ alkyl-, -Co-Cealkyl-S-Co-Csalkyl-, -C ₀ - C ₆ alkyl-S(0)-Co-C ₃ alkyl-, -Co-C ₆ alkyl-S(0) ₂ -Co-C3alkyl-, -Co-C ₆ alkyl-N(R ³ )-C(0)-N(R ³ )- Co-C ₃ alkyl-, -Co-C ₃ alkyl-C=N-0-C ₀ -C ₃ alkyl-, -heterocyclyl-Co-C ₃ alkyl-heterocyclyl-Co- C ₃ alkyl-, -SO ₂ -C ₀ -C ₆ alkyl-heterocyclyl-C ₀ -C ₃ alkyl-, -C(O)-C ₀ -C ₆ alkyl-bridged heterocyclyl- Co-C ₃ alkyl-, -N(R ³ )-C(0)-C ₀ -C ₆ alkyl-heterocyclyl-Co-C ₃ alkyl-, -0-C(0)-Co-C ₆ alkyl- heterocyclyl-Co-C ₃ alkyl-, -N(R ³ )-C(S)-C ₀ -C ₆ alkyl-heterocyclyl-Co-C ₃ alkyl-, -0-C(S)-C ₀ - C ₆ alkyl-heterocyclyl-C ₀ -C ₃ alkyl-, -N(R ³ )-S(O) ₂ -C ₀ -C ₆ alkyl-heterocyclyl-C ₀ -C ₃ alkyl-, -C ₀ - C ₆ alkyl-heterocyclyl-C ₀ -C ₃ alkyl-SO ₂ -N(R ³ )-, -C ₀ -C ₆ alkyl-heterocyclyl-Co-C ₃ alkyl-C(0)- N(R ³ )- and -Co-C6alkyl-heterocyclyl-Co-C ₃ alkyl-C(0)-0-, wherein each alkyl, heterocyclyl and alkenyl moiety is optionally substituted with from one to three substituents independently selected from the group consisting of alkyl, heterocyclyl, C ₂ -C ₆ alkenyl, C ₂ -C ₃ alkynyl, C ₂ - C ₄ alkyl-OR ¹ , heteroalkyl, heteroaryl, C ₀ -C ₆ alkylheteroaryl, C(O)CF ₃ , -C(O)-NH ₂ , -C ₃ - C _δ Cycloalkyl, -alkyl-C^Cecycloalkyl, -Ci-Cβalkylaryl, aryl, alkylheteroaryl and heteroaryl.

32. The comound according to any of claims 1 to 5, wherein Q is an optionally substituted (1R,4R) or (1S,4S) 2,5-diazabicyclo[2.2.1]heptane enantiomer or a mixture of enantiomers, preferably an (1R,4R) enantiomer, more preferably an (1S,4S) enantiomer, selected from the group consisting of

or

Q is absent; or

33. The compound according to claim 1, wherein when is attached to Q via a N in

, then Q is selected from the group consisting of -Ci-Cgalkyl-, -C ₂ -Cealkyl- N(R ³ )-C ₀ -C ₃ alkyl-, -Co-C ₆ alkyl-heterocyclyl-Co-C ₃ alkyl-, -Co-C ₆ alkyl-C(0)-C ₀ -C ₃ alkyl-, -C ₂ -C6alkyl-0-Co-C ₃ alkyl-, -Ci-C6alkyl-(CR ³ =CR ³ )i. ₂ -Co-C6alkyl-, -Ci-C ₆ alkyl-(C≡C)i. ₂ - Co-C ₆ alkyl-, -C ₂ -C ₆ alkyl-N(R ³ )-C(O)-C ₀ -C ₃ alkyl, -C ₂ -C ₆ alkyl-N(R ³ )-C(O)-alkenyl-C ₀ -

C ₃ alkyl, -Co-C ₆ alkyl-C(0)-N(R ³ )-Co-C ₄ alkyl-, -C(O)-O-C ₀ -C ₄ alkyl, -C ₀ -C ₆ alkyl-S(O) ₂ - N(R ³ )-C ₀ -C ₃ alkyl, -C ₂ -C6alkyl-N(R ³ )-S(0) ₂ -Co-C3alkyl, -C ₂ -C ₃ alkyl-N(R ³ )-S(0) ₂ -N(R ³ )- Co-C ₃ alkyl-, -C ₂ -C ₆ alkyl-S-C ₀ -C ₃ alkyl, -C ₂ -C ₆ alkyl-S(O)-C ₀ -C ₃ alkyl, -C ₀ -C ₆ alkyl-S(O) ₂ - Co-C ₃ alkyl, -C ₂ -C ₆ alkyl-N(R ³ )-C(O)-N(R ³ )-C ₀ -C ₃ alkyl, -C ₂ -C ₃ alkyl-C=N-O-C ₀ -C ₃ alkyl, -S0 ₂ -Co-C ₆ alkyl-heterocyclyl-Co-C ₃ alkyl-, -C(0)-Co-C ₆ alkyl-heterocyclyl-Co-C ₃ alkyl-, -N(R ³ )-C(0)-Co-C ₆ alkyl-heterocyclyl-Co-C ₃ alkyl-, -0-C(0)-Co-C ₆ alkyl-heterocyclyl-C ₀ - C ₃ alkyl-, -N(R ³ )-C(S)-Co-C ₆ alkyl-heterocyclyl-Co-C ₃ alkyl-, -0-C(S)-Co-C ₆ alkyl- heterocyclyl-C ₀ -C ₃ alkyl-, - N(R ³ )-S(0) ₂ -Co-C ₆ alkyl-heterocyclyl-Co-C ₃ alkyl-, -C ₀ - C ₆ alkyl-heterocyclyl-C ₀ -C ₃ alkyl-S(O ₂ )-N(R ³ )-, -Co-C ₆ alkyl-heterocyclyl-C ₀ -C ₃ alkyl- C(O)-N(R ³ )- and -C ₀ -C ₆ alkyl-heterocyclyl-Co-C ₃ alkyl-C(0)-0-, wherein each alkyl, heterocyclyl and alkenyl moiety is optionally substituted with from one to three substituents independently selected the group consisting of alkyl, heterocyclyl, C ₂ - Cβalkenyl, C ₂ -C ₃ alkynyl, C ₂ -C ₄ alkyl-OR ¹ , heteroalkyl, heteroaryl, Co-Cβalkylheteroaryl, C(O)CF ₃ , -C(O)-NH ₂ , -C ₃ -C ₆ cycloalkyl, -alkyl-C ₃ -C ₆ cycloalkyl, -Ci-C ₆ alkylaryl, aryl, alkylheteroaryl and heteroaryl, and wherein the heterocyclyl moiety optionally has a bridge Of -(CH ₂ V ₃ -.

34. The compound according to any of claims 1 to 33, wherein each R ₃ is independently selected from the group consisting of -H, alkyl, heterocyclyl, C ₂ -Cealkenyl, C ₂ -C ₃ alkynyl, C ₂ - C ₄ alkyl-OR\ heteroalkyl, heteroaryl, C ₀ -C ₆ alkylheteroaryl, C(O)CF ₃ , -C(O)-NH ₂ , -C ₃ - Cβcycloalkyl, -alkyl-C^Cecycloalkyl, -Ci-Cβalkylaryl, aryl, alkylheteroaryl, heteroaryl and a covalent bond, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl moiety is optionally substituted with from one to three substituents independently selected from the group consisting of alkyl, heterocyclyl, C ₂ -C ₆ alkenyl, C ₂ - C ₃ alkynyl, C ₂ -C ₄ alkyl-OR ¹ , heteroalkyl, heteroaryl, C ₀ -C ₆ alkylheteroaryl, C(O)CF ₃ , -C(O)- NH ₂ , -C ₃ -C ₆ cycloalkyl, -alkyl-C^Cecycloalkyl, -Ci-Cβalkylaryl, aryl, alkylheteroaryl and heteroaryl.

35. The compound according to any of claims 1 to 5, wherein Q-J-L is selected from the group consisting of -C ₃ -C ₈ alkyl-, -C(O)-C ₃ -C ₈ alkyl-, -C ₀ -C ₃ alkyl-O-C ₃ -C ₈ alkyl-, -C ₀ -C ₃ alkyl- Ci-C ₄ alkenyl-C ₀ -C ₃ alkyl-, =N-O-Ci-C ₈ alkyl-, =N-O-C ₀ -C ₃ alkyl-aryl-C ₀ -C ₃ alkyl-, =N-O-C ₀ - C ₃ alkyl-aryl-C ₀ -C ₃ alkenyl-, =N-0-Co-C ₃ alkyl-aryl-C ₀ -C ₃ alkynyl-, =N-O-C ₀ -C ₃ alkyl- heteroaryl-Co-C ₃ alkyl-, =N-0-Co-C ₃ alkyl-heteroaryl-C ₀ -C ₃ alkenyl-, =N-O-C ₀ -C ₃ alkyl- heteroaryl-Co-C ₃ alkynyl-, -C ₀ -C ₃ alkyl-aryl-, -C ₀ -C ₃ alkyl-aryl-C ₀ -C ₃ alkyl-, -C ₀ -C ₃ alkyl-aryl- C ₂ -C ₄ alkenyl-, -Co-C ₃ alkyl-aryl-C ₂ -C ₄ alkynyl-, -Co-C ₃ alkyl-heteroaryl-Co-C ₃ alkyl-, -Ci-

Csalkyl-heteroaryl-Ci-Csalkenyl-, -Ci-Csalkyl-heteroaryl-Ci-Csalkynyl-, -Co-C ₃ alkyl-N(R ³ )- Co-C ₃ alkyl-aryl-Co-C ₃ alkyl-, -Co-C ₃ alkyl-N(R ³ )-Co-C ₃ alkyl-aryl-C ₂ -C ₃ alkenyl-, -Co-C ₃ alkyl- N(R ³ )-C ₀ -C ₃ alkyl-aryl-C ₂ -C ₃ alkynyl-, -Co-C ₃ alkyl-N(R ³ )-Co-C ₃ alkyl-heteroaryl-C ₀ -C ₃ alkyl-, -Co-C ₃ alkyl-N(R ³ )-C ₀ -C ₃ alkyl-heteroaryl-C ₂ -C ₃ alkenyl-, -Co-C ₃ alkyl-N(R ³ )-C _o -C ₃ alkyl- heteroaryl-C ₂ -C ₃ alkynyl-, -Co-C ₃ alkyl-C(0)-N(R ³ )-C ₀ -C ₃ alkyl-aryl-Co-C ₃ alkyl-, -C _o -C ₃ alkyl- C(O)-N(R ³ )-C ₀ -C ₃ alkyl-aryl-C ₂ -C ₃ alkenyl-, -Co-C ₃ alkyl-C(0)-N(R ³ )-C ₀ -C ₃ alkyl-aryl-C ₂ - C ₃ alkynyl-, -Co-C ₃ alkyl-C(0)-N(R ³ )-C ₀ -C ₃ alkyl-heteroaryl-C ₀ -C ₃ alkyl-, -C ₀ -C ₃ alkyl-C(O)- N(R ³ )-C ₀ -C ₃ alkyl-heteroaryl-C ₂ -C ₃ alkenyl-, -Co-C ₃ alkyl-C(0)-N(R ³ )-C ₀ -C ₃ alkyl-heteroaryl- C ₂ -C ₃ alkynyl-, -Co-Csalkyl-heterocyclyl-Co-Csalkyl-aryl-, -Co-Csalkyl-heterocyclyl-Co- C ₃ alkyl-aryl-C ₀ -C ₃ alkyl-, -Co-C ₃ alkyl-heterocyclyl-Co-C ₃ alkyl-aryl-C ₂ -C4alkenyl, -C ₀ - C ₃ alkyl-heterocyclyl-Co-C ₃ alkyl-aryl-C ₂ -C ₄ alkynyl, -Co-Csalkyl-heterocyclyl-Co-Csalkyl- heteroaryl-Co-C ₃ alkyl, -C ₀ -C ₃ alkyl-heterocyclyl-Ci-C ₃ alkyl-heteroaryl-C ₂ -C ₃ alkenyl-, -C ₀ - C ₃ alkyl-heterocyclyl-Ci-C ₃ alkyl-heteroaryl-C ₂ -C ₃ alkynyl-, -C ₂ -C ₄ alkyl-O-C ₀ -C ₃ alkyl-aryl-, -C ₂ -C ₄ alkyl-0-C ₀ -C ₃ alkyl-aryl-Co-C ₃ alkyl-, -C ₂ -C ₄ alkyl-O-C ₀ -C ₃ alkyl-aryl-C ₂ -C ₄ alkenyl, -C ₂ -C ₄ alkyl-O-C ₀ -C ₃ alkyl-aryl-C ₂ -C ₄ alkynyl, -C ₂ -C ₄ alkyl-0-C ₀ -C ₃ alkyl-heteroaryl-Co- C ₃ alkyl, -C ₂ -C ₄ alkyl-O-Ci-C ₃ alkyl-heteroaryl-C ₂ -C ₃ alkenyl- and -C ₂ -C ₄ alkyl-O-Ci-C ₃ alkyl- heteroaryl-C ₂ -C ₃ alkynyl-, wherein each alkyl, alkenyl, aryl, alkynyl, heteroaryl and heterocyclyl moiety is optionally substituted with from one to three substituents independently selected from the group consisting of alkyl, heterocyclyl, C ₂ -Cealkenyl, C ₂ - C ₃ alkynyl, C ₂ -C ₄ alkyl-OR ¹ , heteroalkyl, heteroaryl, C ₀ -C ₆ alkylheteroaryl, C(O)CF ₃ , -C(O)- NH ₂ , -C ₃ -C ₆ cycloalkyl, -alkyl-C ₃ -C ₆ cycloalkyl, -Ci-C ₆ alkylaryl, aryl, alkylheteroaryl and heteroaryl.

36. The compound according to claim 1, wherein selected from the group consisting of hydrogen, aryl, aryl-alkyl-, heteroaryl, heteroaryl-alkyl-, (aryl) ₂ -CH-C ₀ - C ₆ alkyl-, (arylXheteroaryOCH-Co-Cealkyl-, (heteroaryl) ₂ CH-C ₀ -C ₆ alkyl- and (aryl) ₂ -CH-C ₀ - Cealkyl-C(O)-, each of which is optionally substituted with from one to three substituents independently selected from the group consisting of alkyl, heterocyclyl, C ₂ -Cealkenyl, C ₂ - C ₃ alkynyl, C ₂ -C ₄ alkyl-OR ¹ , heteroalkyl, heteroaryl, C ₀ -C ₆ alkylheteroaryl, C(O)CF ₃ , -C(O)- NH ₂ , -C ₃ -C ₆ cycloalkyl, -alkyl-Cs-Cβcycloalkyl, -Ci-Cβalkylaryl, aryl, alkylheteroaryl and heteroaryl, provided that variable n of Q is 0, 1 or 3.

37. The compound according to claim 1, wherein selected from the group consisting of structures (b-1) to (b-121) and Q-J-L taken together is selected from the group consisting of -C ₃ -C ₈ alkyl-, -C(O)-C ₃ -C ₈ alkyl-, -Co-Csalkyl-O-Cs-Cgalkyl-, -C ₀ -C ₃ alkyl-Ci- C ₄ alkenyl-C ₀ -C ₃ alkyl-, =N-O-Ci-C ₈ alkyl-, =N-O-C ₀ -C ₃ alkyl-aryl-C ₀ -C ₃ alkyl-, =N-O-C ₀ - C ₃ alkyl-aryl-C ₀ -C ₃ alkenyl-, =N-0-Co-C ₃ alkyl-aryl-Co-C ₃ alkynyl-, =N-0-Co-C ₃ alkyl- heteroaryl-Co-C ₃ alkyl-, =N-0-Co-C ₃ alkyl-heteroaryl-C ₀ -C ₃ alkenyl-, =N-O-C ₀ -C ₃ alkyl- heteroaryl-Co-C ₃ alkynyl-, -Co-Csalkyl-aryl-Co-Csalkyl-, -Co-C ₃ alkyl-aryl-C ₂ -C ₄ alkenyl-, -C ₀ - C ₃ alkyl-aryl-C ₂ -C ₄ alkynyl-, -Co-Csalkyl-heteroaryl-Co-Csalkyl-, -Co-Csalkyl-heteroaryl-Ci- C ₃ alkenyl-, -C ₀ -C ₃ alkyl-heteroaryl-Ci-C ₃ alkynyl-, -Co-C ₃ alkyl-N(R ³ )-Co-C ₃ alkyl-aryl-C _o - C ₃ alkyl-, -Co-C ₃ alkyl-N(R ³ )-C _o -C ₃ alkyl-aryl-C ₂ -C ₃ alkenyl-, -Co-C ₃ alkyl-N(R ³ )-C _o -C ₃ alkyl- aryl-C ₂ -C ₃ alkynyl-, -Co-C ₃ alkyl-N(R ³ )-Co-C ₃ alkyl-heteroaryl-C ₀ -C ₃ alkyl-, -Co-C ₃ alkyl- N(R ³ )-C ₀ -C ₃ alkyl-heteroaryl-C ₂ -C ₃ alkenyl-, -Co-C ₃ alkyl-N(R ³ )-C ₀ -C ₃ alkyl-heteroaryl-C ₂ - C ₃ alkynyl-, -Co-C ₃ alkyl-C(0)-N(R ³ )-C ₀ -C ₃ alkyl-aryl-Co-C ₃ alkyl-, -Co-C ₃ alkyl-N(R ³ )-C(0)- Co-C ₃ alkyl-aryl-C _o -C ₃ alkyl-, -Co-C ₃ alkyl-C(0)-N(R ³ )-C ₀ -C ₃ alkyl-aryl-C ₂ -C ₃ alkenyl-, -C ₀ - C ₃ alkyl-N(R ³ )-C(O)-C ₀ -C ₃ alkyl-aryl-C ₂ -C ₃ alkenyl-, -Co-C ₃ alkyl-C(0)-N(R ³ )-C ₀ -C ₃ alkyl- aryl-C ₂ -C ₃ alkynyl-, -Co-C ₃ alkyl-N(R ³ )-C(0)-C ₀ -C ₃ alkyl-aryl-C ₂ -C ₃ alkynyl-, -C _o -C ₃ alkyl- C(0)-N(R ³ )-C ₀ -C ₃ alkyl-heteroaryl-Co-C ₃ alkyl-, -Co-C ₃ alkyl-N(R ³ )-C(0)-C ₀ -C ₃ alkyl- heteroaryl-Co-C ₃ alkyl-, -Co-C ₃ alkyl-C(0)-N(R ³ )-C ₀ -C ₃ alkyl-heteroaryl-C ₂ -C ₃ alkenyl-, -C ₀ - C ₃ alkyl-N(R ³ )-C(O)-C ₀ -C ₃ alkyl-heteroaryl-C ₂ -C ₃ alkenyl-, -Co-C ₃ alkyl-C(0)-N(R ³ )-C ₀ - C ₃ alkyl-heteroaryl-C ₂ -C ₃ alkynyl-, -Co-C ₃ alkyl-N(R ³ )-C(0)-C ₀ -C ₃ alkyl-heteroaryl-C ₂ - C ₃ alkynyl-, -Co-C ₃ alkyl-heterocyclyl-Co-C ₃ alkyl-aryl-Co-C ₃ alkyl-, -Co-C ₃ alkyl-C(0)- heterocyclyl-Co-C ₃ alkyl-aryl-C ₀ -C ₃ alkyl-, -Co-C ₃ alkyl-N(R ³ )-C(0)-heterocyclyl-C ₀ -C ₃ alkyl- aryl-C ₀ -C ₃ alkyl-, -Co-C ₃ alkyl-0-C(0)-heterocyclyl-C ₀ -C ₃ alkyl-aryl-Co-C ₃ alkyl-, -C _o -C ₃ alkyl- heterocyclyl-C ₀ -C ₃ alkyl-aryl-C ₂ -C ₄ alkenyl, -Co-C ₃ alkyl-C(0)-heterocyclyl-C ₀ -C ₃ alkyl-aryl- C ₂ -C ₄ alkenyl, -Co-C ₃ alkyl-N(R ³ )-C(0)-heterocyclyl-C ₀ -C ₃ alkyl-aryl-C2-C ₄ alkenyl, -C ₀ - C ₃ alkyl-O-C(O)-heterocyclyl-C ₀ -C ₃ alkyl-aryl-C ₂ -C ₄ alkenyl, -Co-C ₃ alkyl-heterocyclyl-C ₀ - C ₃ alkyl-aryl-C ₂ -C ₄ alkynyl, -Co-C ₃ alkyl-C(0)-heterocyclyl-C ₀ -C ₃ alkyl-aryl-C ₂ -C ₄ alkynyl, -Co-C ₃ alkyl-N(R ³ )-C(0)-heterocyclyl-C ₀ -C ₃ alkyl-aryl-C ₂ -C ₄ alkynyl, -Co-C ₃ alkyl-0-C(0)- heterocyclyl-Co-C ₃ alkyl-aryl-C ₂ -C ₄ alkynyl, -Co-Csalkyl-heterocyclyl-Co-Csalkyl-heteroaryl- Co-C ₃ alkyl, -Co-C ₃ alkyl-C(0)-heterocyclyl-C ₀ -C ₃ alkyl-heteroaryl-Co-C ₃ alkyl, -Co-C ₃ alkyl- N(R ³ )-C(0)-heterocyclyl-C ₀ -C ₃ alkyl-heteroaryl-Co-C ₃ alkyl, -C ₀ -C ₃ alkyl-O-C(O)- heterocyclyl-Co-C ₃ alkyl-heteroaryl-Co-C ₃ alkyl, -Co-Csalkyl-heterocyclyl-Ci-Csalkyl- heteroaryl-C ₂ -C ₃ alkenyl-, -C ₀ -C ₃ alkyl-C(O)-heterocyclyl-Ci-C ₃ alkyl-heteroaryl-C ₂ -

C ₃ alkenyl-, -Co-C3alkyl-N(R ³ )-C(0)-heterocyclyl-Ci-C3alkyl-heteroaryl-C ₂ -C ₃ alkenyl-, -C ₀ -

C ₃ alkyl-O-C(O)-heterocyclyl-Ci-C3alkyl-heteroaryl-C2-C ₃ alkenyl-, -Co-Csalkyl-heterocyclyl-

Ci-C ₃ alkyl-heteroaryl-C ₂ -C ₃ alkynyl-, -Co-C ₃ alkyl-C(0)-heterocyclyl-Ci-C ₃ alkyl-heteroaryl-

C ₂ -C ₃ alkynyl-, -C ₀ -C ₃ alkyl-N(R ³ )-C(O)-heterocyclyl-Ci-C ₃ alkyl-heteroaryl-C ₂ -C ₃ alkynyl-,

-C ₀ -C ₃ alkyl-O-C(O)-heterocyclyl-Ci-C ₃ alkyl-heteroaryl-C ₂ -C ₃ alkynyl-, -C ₂ -C ₄ alkyl-O-C ₀ -

C ₃ alkyl-aryl-, ^^alkyl-O-Co-C^lkyl-aryl-Co-C^lkyl-, -C2-C ₄ alkyl-0-Co-C ₃ alkyl-aryl-C ₂ -

C ₄ alkenyl, -C ₂ -C ₄ alkyl-0-Co-C ₃ alkyl-aryl-C ₂ -C ₄ alkynyl, -C ₂ -C ₄ alkyl-O-C ₀ -C ₃ alkyl- heteroaryl-Co-C ₃ alkyl, -C ₂ -C ₄ alkyl-O-C _l -C ₃ alkyl-heteroaryl-C ₂ -C ₃ alkenyl-, -C ₂ -C ₄ alkyl-O-

Ci-C ₃ alkyl-heteroaryl-C ₂ -C ₃ alkynyl-,

-Co-Cealkyl-U-bridged heterocyclyl-heteroaryl-Co-Cealkyl-,

-Co-C ₆ alkyl-U-bridged heterocyclyl-N(R ³ )-heteroaryl-Co-C ₆ alkyl-,

-Co-C ₆ alkyl-U-N(R ³ )-bridged heterocyclyl-heteroaryl-Co-C ₆ alkyl-,

-Co-Cealkyl-U-bridged heterocyclyl-aryl-Co-Cealkyl-,

-Co-C ₆ alkyl-U-bridged heterocyclyl-N(R ³ )-aryl-Co-C ₆ alkyl-,

-Co-C ₆ alkyl-U-N(R ³ )-bridged heterocyclyl-aryl-Co-C ₆ alkyl-,

-Co-Cealkyl-U-bridged heterocyclyl-aryl^-Cealkenyl-,

-Co-C ₆ alkyl-U-bridged heterocyclyl-N(R ³ )-aryl-C ₂ -C ₆ alkenyl-,

-Co-C ₆ alkyl-U-N(R ³ )-bridged heterocyclyl-aryl-C ₂ -C ₆ alkenyl-,

-Co-C ₆ alkyl-U-bridged heterocyclyl-heteroaryl-C ₂ -C ₆ alkenyl-,

-Co-C ₆ alkyl-U-bridged heterocyclyl-N(R ³ )-heteroaryl-C ₂ -C ₆ alkenyl-,

-Co-C ₆ alkyl-U-N(R ³ )-bridged heterocyclyl-heteroaryl-C ₂ -C ₆ alkenyl-,

-Co-Cealkyl-bridged heterocyclyl-U-heteroaryl-Co-Cealkyl-,

-Co-C ₆ alkyl-N(R ³ )-bridged heterocyclyl-U-heteroaryl-Co-C ₆ alkyl-,

-Co-C ₆ alkyl-bridged heterocyclyl-N(R ³ )-U-heteroaryl-Co-C ₆ alkyl-,

-Co-Cealkyl-bridged heterocyclyl-U-aryl-Co-Cealkyl-,

-Co-C ₆ alkyl-N(R ³ )-bridged heterocyclyl-U-aryl-Co-C ₆ alkyl-,

-Co-C ₆ alkyl-bridged heterocyclyl-N(R ³ )-U-aryl-Co-C ₆ alkyl-,

-Co-C ₆ alkyl-bridged heterocyclyl-U-aryl-C ₂ -C ₆ alkenyl-,

-Co-C ₆ alkyl-N(R ³ )-bridged heterocyclyl-U-aryl-C ₂ -C ₆ alkenyl-,

-Co-C ₆ alkyl-bridged heterocyclyl-N(R ³ )-U-aryl-C ₂ -C ₆ alkenyl-,

-Co-Cealkyl-bridged heterocyclyl-U-heteroaryl^-Cealkenyl-,

-Co-C ₆ alkyl-N(R )-bridged heterocyclyl-U-heteroaryl-C ₂ -C ₆ alkenyl-, and

-Co-C ₆ alkyl-bridged heterocyclyl-N(R ³ )-U-heteroaryl-C ₂ -C ₆ alkenyl-,

wherein each alkyl, alkenyl, aryl, alkynyl, heteroaryl and heterocyclyl moiety is optionally substituted; and wherein the bridge is methylene or propylene.

38. The compound according to claim 1, wherein B-Q-J-L- are taken together, wherein each such B-Q-J-L group is optionally substituted with up to 4 substituents independently selected from the group consisting of hydroxy, amino, halo, Ci-C ₆ alkyl, nitro, cyano, C ₂ - C ₆ alkoxy, Ci-Cβamino and CF ₃ , heterocyclyl, C2-Cealkenyl, C2-C3alkynyl, C ₂ -QaUCyI-OR ¹ , heteroalkyl, heteroaryl, C ₀ -C ₆ alkylheteroaryl, C(O)CF ₃ , -C(O)-NH ₂ , -C^Cgcycloalkyl, -alkyl- C ₃ -C ₆ Cycloalkyl, -Ci-Cβalkylaryl, aryl and alkylheteroaryl.

39. The compound according to any of claims 1 to 38, wherein each R ⁴ is independently selected from the group consisting of -H, d-C ₆ alkyl, C ₂ -C ₆ alkenyl, C ₂ -C ₆ alkynyl, Ci- C ₆ alkyl-R ³ , -C ₀ -C ₆ alkyl-OR ³ , -Co-Cealkyl-OR ¹ , -C ₀ -C ₆ alkyl-C(O)-OR ³ , -C ₀ -C ₆ alkyl- C(O)NR ³ R ^3a , -CH=CH-C(O)-OR ³ , -CH=CH-C(O)-N(R ³ )(R ^3a ), -N(R ³ )-C(O)-CF ³ , -N(R ³ )-C ₂ - C ₆ alkyl-N(R ³ )(R ^3a ), -C ₀ -C ₆ alkyl-N(R ³ )(R ^3a ), -N(R ³ )-C(O)-Ci-C ₆ alkyl-R ³ , -N(R ³ )-S(O) ₂ -Ci- C ₆ alkyl-R ³ , - S(O) ₂ -N(R ³ )R ^3a , -O-C ₂ -C ₆ alkyl-N(R ³ )(R ^3a ), -S-R ³ , -S(O)-Ci-C ₆ alkyl-R ³ , -S(O) ₂ - Ci-C ₆ alkyl-R ³ , C ₃ -C ₆ cycloalkyl, heterocyclyl, C ₄ -C ₇ heterocyclyl-R ³ , -O-C ₂ -C ₄ alkyl- heterocyclyl, -O-heterocyclyl-C(O)-OR ³ , -O-C ₀ -C ₄ alkyl-aryl, -O-C ₀ -C ₄ alkyl-heteroaryl, -O- C(O)-NR ³ -C ₀ -C ₄ alkyl-aryl, -O-C(O)-NR ³ -C ₀ -C ₄ alkyl-heteroaryl, -0-Co-C ₄ alkyl- heterocyclylaryl, -O-Co-Cz _t alkyl-heterocyclyl-heteroaryl, -N(R ³ )-C ₂ -C ₄ alkyl-heterocyclyl, -N(R ³ )C(O)N(R ³ )-C ₀ -C ₄ alkyl-heterocyclyl-R ³ , -Co-C ₄ alkyl-OC(0)-R ³ , -Co-C ₄ alkyl- N(R ³ )C(O)-O-R ³ , -Co-C ₄ alkyl-heterocyclyl-C(0)-0-R ³ , -N(R ³ )-C ₂ -C ₄ alkyl-heterocyclyl, F, Cl, Br, I, NO ₂ , -CF ₃₅ -SO ₃ H, -CN, -Ci-C ₆ alkylaryl, aryl, heteroaryl, -Ci-C ₆ alkylheteroaryl, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl moeity of the aformentioned R ⁴ is optionally substituted with from one to three substituents independently selected from the group consisting of alkyl, heterocyclyl, C ₂ -C ₆ alkenyl, C ₂ - C ₃ alkynyl, C ₂ -C ₄ alkyl-OR ¹ , heteroalkyl, heteroaryl, C ₀ -C ₆ alkylheteroaryl, C(O)CF ₃ , -C(O)- NH ₂ , -C ₃ -C ₆ cycloalkyl, -alkyl-Q-Cβcycloalkyl, -Ci-C ₆ alkylaryl, aryl, alkylheteroaryl and heteroaryl.

40. The compound according to any of claims 1 to 39, wherein each R ^3a is independently selected from the group consisting of -H, alkyl, heterocyclyl, C ₂ -C ₆ alkenyl, C ₂ -C ₃ alkynyl, C ₂ - C ₄ alkyl-OR\ heteroalkyl, heteroaryl, C ₀ -C ₆ alkylheteroaryl, C(O)CF ₃ , -C(O)-NH ₂ , -C ₃ - C ₆ cycloalkyl, -alkyl-Cs-Cβcycloalkyl, -Ci-C ₆ alkylaryl, aryl, alkylheteroaryl and heteroaryl, covalent bond, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocyclyl,

aryl and heteroaryl moiety is optionally substituted with from one to three substituents independently selected from the group consisting of alkyl, heterocyclyl, C2-Cealkenyl, C ₂ - C ₃ alkynyl, C ₂ -C ₄ alkyl-OR ¹ , heteroalkyl, heteroaryl, C ₀ -C ₆ alkylheteroaryl, C(O)CF ₃ , -C(O)- NH ₂ , -C ₃ -C ₆ cycloalkyl, -alkyl-Cs-Cβcycloalkyl, -Ci-C ₆ alkylaryl, aryl, alkylheteroaryl and heteroaryl.

41. The compound according to any of claims 1 to 5, wherein Q is selected from the group consisting of

or an optionally substituted (R,R) or (S, S) enantiomer or a mixture of enantiomers, preferably an (R,R) enantiomer, more preferably an (S, S) enantiomer thereof, each of which is optionally substituted with a substituent selected from the group consisting of halo, alkyl and aryl.

42. The compound according to claim 1, wherein selected from the group consisting of

wherein

-M ^J -M ² - is -CH=CH- or -CH ₂ -CH ₂ -;

A is selected from the group consisting of N, C(R ⁴ ) and CH;

Z is -NHOH;

L is covalent bond;

J is selected from the group consisting of -Ci-Cgalkyl-, -Co-Cealkyl-aryl-Co-Cβalkyl-, -Co-

C ₆ alkyl-aryl-C ₂ -C ₆ alkenyl-, -Co-Cealkyl-heteroaryl-Co-Cealkyl- and -CH=; and Q is selected from the group consisting of covalent bond, =N-O-, -C ₀ -C ₆ alkyl-N(R ³ )-C ₀ -

C ₃ alkyl-, -Co-C ₆ alkyl-N(R ³ )-C(0)-Co-C ₃ alkyl- and -Co-C ₆ alkyl-C(0)-Co-C ₃ alkyl-.

43. The compound according to claim 1, wherein

is further selected from the group consisting of

44. The compound according to claim 1, wherei inn < is selected from the group consisting of

Q is -Co-Cealkyl-.

45. The compound according to claim 1, wherein

, is optionally substituted

W is -CH=CH- or -CH ₂ -CH ₂ -;

Y is selected from the group consisting of N, C(R ⁴ ) and CH;

Z is -NHOH;

L is covalent bond;

J is selected from the group consisting of -Ci-Csalkyl-, -Co-Cealkyl-aryl-Co-Cβalkyl-, -Co-

C ₆ alkyl-aryl-C ₂ -C ₆ alkenyl-, -Co-Cealkyl-heteroaryl-Co-Cβalkyl- and -CH=; and

Q is selected from the group consisting of covalent bond, =N-O-, -Co-Cealkyl-N(R )-Co-

C ₃ alkyl-, -C ₀ -C ₆ alkyl-N(R ³ )-C(0)-Co-C ₃ alkyl- and -C ₀ -C ₆ alkyl-C(0)-Co-C ₃ alkyl-.

46. The compound according to claim 1, wherein

is selected from the group consisting of

each of which is optionally substituted on a phenyl ring with one or two R ⁴ ;

Z iS -NR ¹ OR ² Or H;

R ¹ and R ² are -H;

L is covalent bond or -N(OH)-;

J is -Ci-Csalkyl-, -Co-Cealkyl-aryl-Co-Cealkyl-, -Co-Cealkyl-heteroaryl-Co-Cealkyl-, -C ₀ - C ₃ alkyl-C ₂ -C ₆ alkenyl-Co-C ₃ alkyl-, -Co-C ₆ alkyl-aryl-C ₂ -C ₆ alkenyl- and -C ₂ -C ₆ alkenyl- aryl-Co-C ₆ alkyl-;

Q is selected from the group consisting of covalent bond, -Ci-C ₃ alkyl-(C≡C)-Co-C ₃ alkyl, -Co- C ₆ alkyl-, -Ci-C ₃ alkyl-(CH=CH)-C ₀ -C ₃ alkyl-, -C ₂ -C ₆ alkyl-0-Co-C ₃ alkyl-, -C ₂ -C ₆ alkyl- C(O)-C ₀ -C ₃ alkyl- and -C ₂ -C ₆ alkyl-heterocyclyl-Co-C ₃ alkyl-; or

Q is selected from the group consisting of a covalent bond, -Ci-C ₃ alkyl-(C≡C)-C ₀ -C ₃ alkyl, -Co-C ₆ alkyl-, -Ci-C ₃ alkyl-(CH=CH)-C ₀ -C ₃ alkyl-, -Co-C ₆ alkyl-0-Co-C ₃ alkyl-, -C ₀ -

C ₆ alkyl-C(O)-C ₀ -C ₃ alkyl- and -Co-Cealkyl-heterocyclyl-Co-Csalkyl- when is

and

R ³ is H or cycloalkyl.

47. The compound according to claim 1, wherein

is selected from the group consisting of (aryl) ₂ -CH-Co-C ₆ alkyl-, (aryl) ₂ -Ci-C ₆ alkyl- and (heteroaryl) ₂ -Ci-C ₆ alkyl-, wherein each aryl, alkyl and heteroaryl moiety is optionally substituted;

Z is NHOH;

Q is selected from the group consisting of -Co-Cealkyl-heteroaryl-Co-Cβalkyl-, =N-O-, -Co- C ₆ alkyl-heterocyclyl-C ₀ -C ₃ alkyl and -C ₀ -C ₆ alkyl-O-C ₀ -C ₃ alkyl;

J is -Co-Cealkyl-heteroaryl-Co-Cβalkyl; and

L is a covalent bond.

48. The compound according to claim 1, wherein

selected from the group consisting of aryl and (aryl) ₂ -alkyl, each of which is optionally substituted and H;

Q is selected from the group consisting of -Co-Cβalkyl-bridged heterocyclyl-Co-Csalkyl- and

J is -Co-Cealkyl-heteroaryl-Co-Cβalkyl; L is a covalent bond; and Z is NHOH.

49. The compound according to claim 1, wherein

R ^j is H or alkyl;

L is covalent bond;

J is -Ci-Csalkyl- or -Co-Csalkyl-Ci-Csalkenyl-Co-Csalkyl-; and

Q is covalent bond.

50. The compound according to claim 1, wherein

is Z is -NHOH;

L is a covalent bond;

J is -Ci-Cgalkyl- or -Co-Cealkyl-aryl^-Cealkenyl-; and

Q is a covalent bond.

51. The compound according to claim 1, selected from one of the following structures:

wherein A is N or -CH=.

52. A compound represented by the Formula (II):

( ) and N-oxides, hydrates, solvates, pharmaceutically acceptable salts, prodrugs, polymorphs and complexes thereof, and racemic and scalemic mixtures, diastereomers and enantiomers thereof, wherein

Z is selected from the group consisting of -N(R^OR ² and H;

L is selected from the group consisting of a covalent bond and -N(OR ² )-; wherein, when L is -N(OR ² )-, then Z is H; and wherein, when Z is H, then L is -N(OR ² )-;

R ¹ and R ² are independently selected from the group consisting of -H and Ci-Cβalkyl;

W is nitrogen or carbon;

D ^la -D ^2a is selected from the group consisting of

wherein, * represents the point of attachment to Q;

D ³ is independently selected from the group consisting of -C(R ⁵⁵ )(R ⁶⁶ )-, -C(R ⁵⁵ )(OH)-,

-C(O)-, -0-, -N(R 7"7 _λ )- and -S(O) _0-2 -;

and are independently selected from the group consisting of phenyl, heteroaryl and heterocyclyl, wherein each phenyl, heteroaryl and heterocyclyl is optionally substituted with one to three substituents independently selected from the group consisting of halo, -CF ₃ , -OCF ₃ , -NO ₂ , -CN, -Ci-C ₆ alkyl, -Ci-C ₆ alkoxyl, -O-C ₂ -C ₆ alkyl- O-R ⁵³ , -O-R ⁵³ , -Co-C ₆ alkyl-S(0) ₀ -2-R ⁵³ , -C ₀ -C ₆ alkyl-C(O)-R ⁵³ , -C ₀ -C ₆ alkyl-C(O)NR ⁵⁰ R ⁵¹ , -C ₀ -C ₆ alkyl- NR ⁵² C(O)-R ⁵³ , -C ₀ -C ₆ alkyl-S(O) ₂ NR ⁵⁰ R ⁵¹ , -C ₀ -C ₆ alkyl- NR ⁵² S(O) ₂ -R ⁵³ , -C ₀ - C ₆ alkyl-OC(O)NR ⁵⁰ R ⁵¹ , -C ₀ -C ₆ alkyl- NR ⁵² C(O)O-R ⁵³ , -C ₀ -C ₆ alkyl- NR ⁵² C(O)NR ⁵⁰ R ⁵¹ , -Co-C ₆ alkyl-C(0)0-R ⁵³ , -C ₀ -C ₆ alkyl-OC(O)-R ⁵³ , -C ₀ -C ₆ alkyl-aryl, -C ₀ -C ₆ alkyl- heteroaryl, -Co-Cealkyl-Cs-Cycycloalkyl, -Co-Cealkyl-heterocyclyl, -C ₀ -C ₆ alkyl-NR ⁵⁰ R ⁵¹ , -O-C ₂ -C ₆ alkyl-NR ⁵⁰ R ⁵¹ , -NR ⁵³ -C ₂ -C ₆ alkyl-NR ⁵⁰ R ⁵¹ and -O-heterocyclyl- R ⁵³ ;

R ⁴⁴ is independently selected from the group consisting of -H, -Ci-Cβalkyl, -Co-Cealkyl-C ₃ - Cycycloalkyl and -Co-C4alkyl-heterocyclyl;

R ⁵⁰ and R ⁵¹ are independently selected from the group consisting of H, -Ci-Cβalkyl, -C ₂ - Cealkyl-O-Ci-Cβalkyl, -Co-Cβalkyl-Q-Cycycloalkyl, wherein each alkyl and cycloalkyl is optionally substituted with one or more substituents independently selected from the group consisting of halo, -OH, amino, -CN or -Ci-C ₄ alkyl; or

R ⁵⁰ and R ⁵¹ , together with the N atom to which they are attached, optionally form a 3-10 membered heterocyclic ring, wherein the heterocyclyl is optionally substituted with one to three substituents independently selected from the group consisting of halo, -OH, amino, -CN or -Ci-C ₄ alkyl;

R ⁵² is independently selected from the group consisting of -H, -Ci-Cβalkyl, -C ₂ -C ₆ alkyl-O-Ci- Cβalkyl, -Co-C ₆ alkyl-C ₃ -Cycycloalkyl, wherein each alkyl and cycloalkyl is optionally substituted with one or more substituents independently selected from the group consisting of halo, -OH, amino, -CN or -Ci-C ₄ alkyl;

R ⁵³ is independently selected from the group consisting of -Ci-C ₆ alkyl, -C ₀ -C ₄ alkyl-C ₃ - Cycycloalkyl, -Co-C ₄ alkyl-aryl, -Co-C ₄ alkyl-heteroaryl and -Co^alkyl-heterocyclyl, wherein each alkyl, aryl, heteroaryl and heterocyclyl is optionally substituted with one or three substituents independently selected from the group consisting of halo, -OH, amino, -CN or -Ci-C ₄ alkyl;

R ⁵⁵ and R ⁶⁶ are independently selected from the group consisting of -H, -Ci-Cβalkyl, -Ci- Cβalkoxyl, -Co-C4alkyl-C ₃ -Cycycloalkyl and -Co^alkyl-heterocyclyl;

or

R ⁵⁵ and R ⁶⁶ , together with the atom to which they are attached, optionally form a 3-7 membered cycloalkyl or heterocyclic ring, wherein each cycloalkyl and heterocyclyl is optionally substituted with one to three substituents independently selected from the group consisting of halo, -OH, amino, -CN or -Ci-C ₄ alkyl;

R ⁷⁷ is independently selected from the group consisting of -H, -Ci-Cβalkyl, -Ci-Cβheteroalkyl, -Cs-Cycycloalkyl, -C(O)-R ⁵³ , -C(O)O-R ⁵³ , -cycloalkyl, -Ci-C ₄ alkyl-cycloalkyl, phenyl, -Ci-C ₄ alkyl-phenyl, -heterocyclyl, -Ci-C ₄ alkyl-heterocyclyl and -C ₂ -C ₆ alkyl-NR ⁸⁸ R ⁹⁹ , wherein each alkyl and heteroalkyl is optionally substituted with one or three substituents independently selected from the group consisting of F, -OH and oxo, wherein each phenyl, cycloalkyl and heterocyclyl is optionally substituted with one or two substituents independently selected from the group consisting of halo, -CN, -Ci-C ₄ alkyl, -Ci- C ₄ alkoxyl, -O-C ₂ -C ₄ alkyl-O-Ci-C ₄ alkyl, -CF ₃ , -OCF ₃ , -NO ₂ , -Ci-C ₆ alkyl-S(O) ₀ - ₂ R ⁵³ ,

-NH ₂ , -NR ⁵⁰ R ⁵¹ , -Ci-C ₆ alkyl-NR ⁵⁰ R ⁵¹ and -N(Ci-C ₆ alkyl) ₂ ;

or R > 77 _. together with the N to which it is attached may form a ring with wherein the ring is a 5-7 membered heterocyclic ring, and

R ⁸⁸ and R ⁹⁹ are independently selected from the group consisting of -H, -Ci-Cβalkyl, -C ₂ - Cealkyl-O-Ci-Cβalkyl and -Co-C ₄ alkyl-C ₃ -C ₇ cycloalkyl, wherein each cycloalkyl and alkyl is optionally substituted with one to three substituents independently selected from the group consisting of halo, -OH, amino, -CN or -Ci-Cβalkyl-aryl; or

R ⁸⁸ and R ⁹⁹ , together with the N atom to which they are attached, optionally form a 3-10 membered heterocyclic ring, wherein an heterocyclyl is optionally substituted with one to three substituents independently selected from the group consisting of halo, -OH, amino or -CN

53. The compound according to claim 52, wherein

J-Q is selected from the group consisting of -Ci-Cgalkyl, -Ci-Cgheteroalkyl, phenyl, aryl, heteroaryl, -Ci-C ₄ alkyl-phenyl, -Ci-C ₄ alkyl-aryl, -Ci-C ₄ alkyl-heteroaryl, -NR ³³ aryl, -NR ³³ -Ci-C ₄ alkyl-aryl, -NR ³³ heteroaryl and NR ³³ -Ci-C ₄ alkyl-heteroaryl, wherein each alkyl and heteroalkyl is optionally substituted with one or three substituents independently selected from the group consisting of F, -OH and oxo, and wherein each phenyl, aryl and heteroaryl is optionally substituted with one or two substituents

independently selected from the group consisting of halo, -OH, -OR ⁵³ , -Ci-C4alkyl, -C ₁ - C ₄ alkoxyl, -O-C ₂ -C ₄ alkyl-O-Ci-C ₆ alkyl,-CN, -CF ₃ , -OCF ₃ , -NO ₂ , -Ci-C ₆ alkyl-S(0)o- ₂ R ⁵³ , -NH ₂ , -NR ⁵⁰ R ⁵¹ , -Ci-C ₆ alkyl-NR ⁵⁰ R ⁵¹ and -N(Ci-C ₆ alkyl) ₂ , wherein R ³³ is independently selected from the group consisting of -H, -d-C ₆ alkyl, -Co-C ₆ alkyl-C ₃ -C ₇ cycloalkyl and -Co-C ₄ alkyl-phenyl, wherein each phenyl and cycloalkyl is optionally substituted with one or three substituents independently selected from the group consisting of halo, -OH, -NO ₂ , -CF ₃ , -OCF ₃ , amino, -N(Ci-C ₆ alkyl) ₂ , -Ci-C ₆ alkyl-S(O) ₀ - ₂ R ⁵³ , -Ci-C ₄ alkoxyl -CN, -O-C ₂ alkyl-O-CH ₃ , -NR ⁵⁰ R ⁵¹ , -Ci-C ₆ alkyl-NR ⁵⁰ R ⁵¹ or -Ci-C ₄ alkyl.

54. The compound according to claim 52 or claim 53, wherein

55. The compound according to any of claims 52 to 54, wherein J-Q is selected from the group consisting of 5- or 6-membered heteroaryl.

56. The compound according to claim 52, represented by the Formula (III):

wherein

R ¹⁴⁰ is selected from the group consisting of H, -OH, halo, -CN, -Ci-C ₄ alkyl, -Ci-C ₄ alkoxyl, -O-C ₂ -C ₄ alkyl-O-Ci-C ₄ alkyl, -CF ₃ , -OCF ₃ , -NO ₂ , -Ci-C ₆ alkyl-S(O) ₀ - ₂ R ⁵³ , -NH ₂ , -NR ⁵⁰ R ⁵¹ , -Ci-C ₆ alkyl-NR ⁵⁰ R ⁵¹ and -N(Ci-C ₆ alkyl) ₂ .

57. The compound according to claim 56, wherein

D la ^a - rD-v2a ^a i •s selected from the group consisting of

58. The compound according to claim 56, wherein

D ^la -D ^2a is .

59. The compound according to claim 56, wherein

D ³ is selected from the group consisting of -C(R ⁵⁵ )(R ⁶⁶ )-, -C(R ⁵⁵ )(OH)-, -C(O)-, -O-,

-N(R ⁷⁷ )- and -S(O) _0-2 .

60. The compound according to claim 56, wherein

D ^la -D ^2a is ; and

D ³ is -N(R ⁷⁷ )-.

61. The compound according to claim 56, wherein

D ^la -D ^2a is ; and D ³ is -O-.

62. The compound according to claim 56, wherein

D ^la -D ^2a is

D is -O-; and

are independently selected from the group consisting of phenyl, pyridyl, pyrimidyl, thienyl, pyrazolyl, thiazyl and oxazyl.

63. The compound according to claim 56, wherein

D ^la -D ^2a is D ³ is -O-; and

are i ndependently selected from the group consisting of phenyl, pyridyl,

pyrimidyl, thienyl, pyrazolyl, thiazyl and oxazyl, wherein at least one of ^—W and is phenyl, wherein the phenyl, pyridyl, pyrimidyl, thienyl, pyrazolyl, thiazyl and oxazyl are independently optionally substituted.

64. The compound according to claim 56, wherein

D ^la -D ^2a is ;

D ³ is -N(R ⁷⁷ )-; and

are independently selected from the group consisting of phenyl, pyridyl, pyrimidyl and thienyl.

65. The compound according to claim 56, wherein

D ^la -D ^2a is ;

D ³ is -N(R ⁷⁷ )-; and

are independently selected from the group consisting of phenyl, pyridyl,

pyrimidyl and thienyl, wherein at least one of V ^-.J "' : i _s s phenyl, wherein said phenyl, pyridyl, pyrimidyl and thienyl are independently optionally substituted.

66. The compound according to claim 56, represented by the Formula (IV):

wherein

R ¹⁴⁰ is selected from the group consisting of H, -OH, halo, -CN, -Ci-C ₄ alkyl, -Ci-C ₄ alkoxyl,

-O-C ₂ -C ₄ alkyl-O-Ci-C ₄ alkyl, -CF ₃ , -OCF ₃ , -NO ₂ , -Ci-C ₆ alkyl-S(0)o- ₂ R ⁵³ , -NH ₂ ,

-NR ⁵⁰ R ⁵¹ , -Ci-C ₆ alkyl-NR ⁵⁰ R ⁵¹ and -N(Ci-C ₆ alkyl) ₂ ; xa and xb denote numbers that are each independently selected from 0, 1 and 2; and

R ¹⁵⁰ and R ¹⁶⁰ are independently selected from the group consisting of H, halo, -CN, -CF ₃ , -OCF ₃ , -Ci-Cealkyl, -Ci-C ₆ alkoxyl, -O-C ₂ -C ₆ alkyl-O-R ⁵³ , -OR ⁵³ , -C ₀ -C ₆ alkyl-S(O) ₀ - ₂ -R ⁵³ , -Co-C ₆ alkyl-C(0)-R ⁵³ , -C ₀ -C ₆ alkyl-C(O)NR ⁵⁰ R ⁵¹ , -C ₀ -C ₆ alkyl- NR ⁵² C(O)-R ⁵³ , -C ₀ - C ₆ alkyl-S(O) ₂ NR ⁵⁰ R ⁵¹ , -C ₀ -C ₆ alkyl- NR ⁵² S(O) ₂ -R ⁵³ , -C ₀ -C ₆ alkyl-OC(O)NR ⁵⁰ R ⁵¹ , -C ₀ - C ₆ alkyl- NR ⁵² C(O)O-R ⁵³ , -C ₀ -C ₆ alkyl- NR ⁵² C(O)NR ⁵⁰ R ⁵¹ , -C ₀ -C ₆ alkyl-C(O)O-R ⁵³ , -C ₀ - C ₆ alkyl-OC(O)-R ⁵³ , -C ₀ -C ₆ alkyl-aryl, -Co-Cealkyl-heteroaryl, -Co-Cealkyl-cycloalkyl, -Co-Cealkyl-heterocyclyl, -NH ₂ , -NR ⁵⁰ R ⁵¹ , -Ci-C ₆ alkyl-NR ⁵⁰ R ⁵¹ , -O-C ₂ -C ₆ alkyl-NR ⁵⁰ R ⁵¹ , -NR ⁵³ -C ₂ -C ₆ alkyl-NR ⁵⁰ R ⁵¹ and -O-heterocyclyl- R ⁵³ , wherein each alkyl and heteroalkyl is optionally substituted with one or three substituents independently selected from the group consisting of F, -OH and oxo, and wherein each aryl, heteroaryl, cycloalkyl and heterocyclyl is optionally substituted with one or two substituents independently selected from the group consisting of halo, -CN, -Ci-C ₄ alkyl, -Ci-C ₄ alkoxyl, -O-C ₂ -C ₄ alkyl-O-Cr C ₄ alkyl, -CF ₃ , -OCF ₃ , -NO ₂ , -Ci-C ₆ alkyl-S(O) ₀ - ₂ R ⁵³ , -NH ₂ , -NR ⁵⁰ R ⁵¹ , -Ci-C ₆ alkyl- NR ⁵⁰ R ⁵¹ and -N(Ci-C ₆ alkyl) ₂ ;

R ⁵⁰ and R ⁵¹ are independently selected from the group consisting of H, -Ci-Cβalkyl, -C ₂ - Cealkyl-O-Ci-Cβalkyl, -Co-C ₆ alkyl-C ₃ -Cvcycloalkyl, wherein each alkyl and cycloalkyl is optionally substituted with one or more substituents independently selected from the group consisting of halo, -OH, amino, -CN or -Ci-C ₄ alkyl; or

R ⁵⁰ and R ⁵¹ , together with the N atom to which they are attached, optionally form a 3-10 membered heterocyclic ring, wherein the heterocyclyl is optionally substituted with one to three substituents independently selected from the group consisting of halo, -OH, amino, -CN or -Ci-C ₄ alkyl;

R ⁵² is independently selected from the group consisting of -H, -Ci-Cβalkyl, -C ₂ -C6alkyl-O-Ci- Cβalkyl, -Co-C ₆ alkyl-C ₃ -C ₇ cycloalkyl, wherein each alkyl and cycloalkyl is optionally substituted with one or more substituents independently selected from the group consisting of halo, -OH, amino, -CN or -Ci-C ₄ alkyl;

R ⁵³ is independently selected from the group consisting of -Ci-Cβalkyl, -Co-C ₄ alkyl-C ₃ - Cycycloalkyl, -Co-C-ialkyl-aryl, -Co-C4alkyl-heteroaryl and -Co^alkyl-heterocyclyl, wherein each alkyl, aryl, heteroaryl and heterocyclyl is optionally substituted with one or three substituents independently selected from the group consisting of halo, -OH, amino, -CN or -Ci-C ₄ alkyl.

67. The compound according to claim 66, represented by the Formula (V):

wherein

R ¹⁴⁰ is selected from the group consisting of H, -OH, halo, -CN, -Ci-C ₄ alkyl, -Ci-C ₄ alkoxyl, -O-C ₂ -C ₄ alkyl-O-Ci-C ₄ alkyl, -CF ₃ , -OCF ₃ , -NO ₂ , -Ci-C ₆ alkyl-S(O) ₀ . ₂ R ⁵³ , -NH ₂ , -NR ⁵⁰ R ⁵¹ , -Ci-C ₆ alkyl-NR ⁵⁰ R ⁵¹ and -N(Ci-C ₆ alkyl) ₂ ; xb denotes a number selected from O, 1 and 2; and

R ¹⁵⁰ and R ¹⁶⁰ are independently selected from the group consisting of H, halo, -CN, -CF ₃ , -OCF ₃ , -Ci-Cealkyl, -Ci-C ₆ alkoxyl, -O-C ₂ -C ₆ alkyl-O-R ⁵³ , -OR ⁵³ , -Co-C ₆ alkyl-S(0)o- ₂ -R ⁵³ , -Co-C ₆ alkyl-C(0)-R ⁵³ , -C ₀ -C ₆ alkyl-C(O)NR ⁵⁰ R ⁵¹ , -C ₀ -C ₆ alkyl- NR ⁵² C(O)-R ⁵³ , -C ₀ - C ₆ alkyl-S(O) ₂ NR ⁵⁰ R ⁵¹ , -C ₀ -C ₆ alkyl- NR ⁵² S(O) ₂ -R ⁵³ , -C ₀ -C ₆ alkyl-OC(O)NR ⁵⁰ R ⁵¹ , -C ₀ - C ₆ alkyl- NR ⁵² C(O)O-R ⁵³ , -C ₀ -C ₆ alkyl- NR ⁵² C(O)NR ⁵⁰ R ⁵¹ , -C ₀ -C ₆ alkyl-C(O)O-R ⁵³ , -C ₀ - C ₆ alkyl-OC(O)-R ⁵³ , -C ₀ -C ₆ alkyl-aryl, -Co-Cealkyl-heteroaryl, -Co-Cealkyl-cycloalkyl,

-Co-Cealkyl-heterocyclyl, -NH ₂ , -NR ⁵⁰ R ⁵¹ , -Ci-C ₆ alkyl-NR ⁵⁰ R ⁵¹ , -O-C ₂ -C ₆ alkyl-NR ⁵⁰ R ⁵¹ , -NR ⁵³ -C ₂ -C ₆ alkyl-NR ⁵⁰ R ⁵¹ and -O-heterocyclyl- R ⁵³ , wherein each alkyl and heteroalkyl is optionally substituted with one or three substituents independently selected from the group consisting of F, -OH and oxo, and wherein each aryl, heteroaryl, cycloalkyl and heterocyclyl is optionally substituted with one or two substituents independently selected from the group consisting of halo, -CN, -Ci-C ₄ alkyl, -Ci-C ₄ alkoxyl, -O-C ₂ -C ₄ alkyl-O-Ci- C ₄ alkyl, -CF ₃ , -OCF ₃ , -NO ₂ , -Ci-C ₆ alkyl-S(O) ₀ - ₂ R ⁵³ , -NH ₂ , -NR ⁵⁰ R ⁵¹ , -Ci-C ₆ alkyl- NR ⁵⁰ R ⁵¹ and -N(d-C ₆ alkyl) ₂ ; xc is 0 or 1 ; and

R ¹⁷⁰ is selected from the group consisting of H, halo, -CN, -CF ₃ , -OCF ₃ , -Ci-Cβalkyl, -Ci- C ₆ alkoxyl, -O-C ₂ -C ₆ alkyl-O-R ⁵³ , -OR ⁵³ , -C ₀ -C ₆ alkyl-S(O) ₀ . ₂ -R ⁵³ , -C ₀ -C ₆ alkyl-C(O)-R ⁵³ , -Co-C ₆ alkyl-C(0)NR ⁵⁰ R ⁵¹ , -C ₀ -C ₆ alkyl- NR ⁵² C(O)-R ⁵³ , -C ₀ -C ₆ alkyl-S(O) ₂ NR ⁵⁰ R ⁵¹ , -C ₀ - C ₆ alkyl- NR ⁵² S(O) ₂ -R ⁵³ , -C ₀ -C ₆ alkyl-OC(O)NR ⁵⁰ R ⁵¹ , -C ₀ -C ₆ alkyl- NR ⁵² C(O)O-R ⁵³ , -C ₀ - C ₆ alkyl- NR ⁵² C(O)NR ⁵⁰ R ⁵¹ , -C ₀ -C ₆ alkyl-C(O)O-R ⁵³ , -C ₀ -C ₆ alkyl-OC(O)-R ⁵³ , -C ₀ - C ₆ alkyl-aryl, -Co-Cβalkyl-heteroaryl, -Co-Cβalkyl-cycloalkyl, -Co-Cβalkyl-heterocyclyl, -NH ₂ , -NR ⁵⁰ R ⁵¹ , -Ci-C ₆ alkyl-NR ⁵⁰ R ⁵¹ , -O-C ₂ -C ₆ alkyl-NR ⁵⁰ R ⁵¹ , -NR ⁵³ -C ₂ -C ₆ alkyl- NR ⁵⁰ R ⁵¹ and -O-heterocyclyl- R ⁵³ , wherein each alkyl and heteroalkyl is optionally substituted with one or three substituents independently selected from the group consisting of F, -OH and oxo, wherein each aryl, heteroaryl, cycloalkyl and heterocyclyl is optionally substituted with one or two substituents independently selected from the group consisting of halo, -CN, -Ci-C ₄ alkyl, -Ci-C ₄ alkoxyl, -O-C ₂ -C ₄ alkyl-O-Ci-C ₄ alkyl, -CF ₃ , -OCF ₃ , -NO ₂ , -Ci-C ₆ alkyl-S(0)o- ₂ R ⁵³ , -NH ₂ , -NR ⁵⁰ R ⁵¹ , -Ci-C ₆ alkyl-NR ^5O R ⁵¹ and -N(d-C ₆ alkyl) ₂

R ⁵⁰ and R ⁵¹ are independently selected from the group consisting of H, -Ci-Cβalkyl, -C ₂ - Cealkyl-O-Ci-Cβalkyl, -Co-Cealkyl-d-Cycycloalkyl, wherein each alkyl and cycloalkyl is optionally substituted with one or more substituents independently selected from the group consisting of halo, -OH, amino, -CN or -Ci-C ₄ alkyl; or

R ⁵⁰ and R ⁵¹ , together with the N atom to which they are attached, optionally form a 3-10 membered heterocyclic ring, wherein the heterocyclyl is optionally substituted with one to three substituents independently selected from the group consisting of halo, -OH, amino, -CN or -Ci-C ₄ alkyl;

R > 52 . is independently selected from the group consisting of -H, -Ci-Cβalkyl, -C ₂ -C ₆ alkyl-O-Ci- Cβalkyl, -Co-Cβalkyl-Cs-Cvcycloalkyl, wherein each alkyl and cycloalkyl is optionally substituted with one or more substituents independently selected from the group consisting of halo, -OH, amino, -CN or -Ci-C ₄ alkyl;

R ⁵³ is independently selected from the group consisting of -Ci-Cβalkyl, -Co-C ₄ alkyl-C ₃ - Cycycloalkyl, -Co-C ₄ alkyl-aryl, -Co-C ₄ alkyl-heteroaryl and -Co^alkyl-heterocyclyl, wherein each alkyl, aryl, heteroaryl and heterocyclyl is optionally substituted with one or three substituents independently selected from the group consisting of halo, -OH, amino, -CN or -Ci-C ₄ alkyl;

68. The compound according to claim 67, represented by the Formula (VI):

( )

69. The compound according to claim 56, represented by the Formula (VII):

wherein R ¹⁴⁰ is selected from the group consisting of H, -OH, halo, -CN, -Ci-C ₄ alkyl, -Ci-C ₄ alkoxyl,

-O-C ₂ -C ₄ alkyl-O-Ci-C ₄ alkyl, -CF ₃ , -OCF ₃ , -NO ₂ , -Ci-C ₆ alkyl-S(0)o- ₂ R , 53 , -NH ₂ , -NR ⁵⁰ R ⁵¹ , -Ci-C ₆ alkyl-NR ⁵⁰ R ⁵¹ and -N(Ci-C ₆ alkyl) ₂ ; xa and xb denote numbers that are each independently selected from O, 1 and 2; and

R ¹⁵⁰ and R ¹⁶⁰ are independently selected from the group consisting of H, halo, -CN, -CF ₃ , -OCF ₃ , -Ci-Cealkyl, -Ci-C ₆ alkoxyl, -O-C ₂ -C ₆ alkyl-O-R ⁵³ , -OR ⁵³ , -C ₀ -C ₆ alkyl-S(O) ₀ -2-R ⁵³ , -Co-C ₆ alkyl-C(0)-R ⁵³ , -C ₀ -C ₆ alkyl-C(O)NR ⁵⁰ R ⁵¹ , -C ₀ -C ₆ alkyl- NR ⁵² C(O)-R ⁵³ , -C ₀ - C ₆ alkyl-S(O) ₂ NR ⁵⁰ R ⁵¹ , -C ₀ -C ₆ alkyl- NR ⁵² S(O) ₂ -R ⁵³ , -C ₀ -C ₆ alkyl-OC(O)NR ⁵⁰ R ⁵¹ , -C ₀ - C ₆ alkyl- NR ⁵² C(O)O-R ⁵³ , -C ₀ -C ₆ alkyl- NR ⁵² C(O)NR ⁵⁰ R ⁵¹ , -C ₀ -C ₆ alkyl-C(O)O-R ⁵³ , -C ₀ - C ₆ alkyl-OC(O)-R ⁵³ , -C ₀ -C ₆ alkyl-aryl, -Co-Cealkyl-heteroaryl, -Co-Cealkyl-cycloalkyl, -Co-Cealkyl-heterocyclyl, -NH ₂ , -NR ⁵⁰ R ⁵¹ , -Ci-C ₆ alkyl-NR ⁵⁰ R ⁵¹ , -O-C ₂ -C ₆ alkyl-NR ⁵⁰ R ⁵¹ , -NR ⁵³ -C ₂ -C ₆ alkyl-NR ⁵⁰ R ⁵¹ and -O-heterocyclyl- R ⁵³ , wherein each alkyl and heteroalkyl is optionally substituted with one or three substituents independently selected from the group consisting of F, -OH and oxo, and wherein each aryl, heteroaryl, cycloalkyl and heterocyclyl is optionally substituted with one or two substituents independently selected from the group consisting of halo, -CN, -Ci-C ₄ alkyl, -Ci-C ₄ alkoxyl, -O-C ₂ -C ₄ alkyl-O-Ci- C ₄ alkyl, -CF ₃ , -OCF ₃ , -NO ₂ , -Ci-C ₆ alkyl-S(O) ₀ - ₂ R ⁵³ , -NH ₂ , -NR ⁵⁰ R ⁵¹ , -Ci-C ₆ alkyl- NR ⁵⁰ R ⁵¹ and -N(Ci-C ₆ alkyl) ₂ ;

R ⁵⁰ and R ⁵¹ are independently selected from the group consisting of H, -Ci-Cβalkyl, -C ₂ - Cealkyl-O-Ci-Cβalkyl, -Co-C ₆ alkyl-C ₃ -Cvcycloalkyl, wherein each alkyl and cycloalkyl is optionally substituted with one or more substituents independently selected from the group consisting of halo, -OH, amino, -CN or -Ci-C ₄ alkyl; or

R ⁵⁰ and R ⁵¹ , together with the N atom to which they are attached, optionally form a 3-10 membered heterocyclic ring, wherein the heterocyclyl is optionally substituted with one to three substituents independently selected from the group consisting of halo, -OH, amino, -CN or -Ci-C ₄ alkyl;

R ⁵² is independently selected from the group consisting of -H, -Ci-Cβalkyl, -C ₂ -C6alkyl-O-Ci- Cβalkyl, -Co-C ₆ alkyl-C ₃ -Cvcycloalkyl, wherein each alkyl and cycloalkyl is optionally substituted with one or more substituents independently selected from the group consisting of halo, -OH, amino, -CN or -Ci-C ₄ alkyl;

R ⁵³ is independently selected from the group consisting of -Ci-Cβalkyl, -Co-C ₄ alkyl-C ₃ - Cycycloalkyl, -C ₀ -C ₄ alkyl-aryl, -C ₀ -C ₄ alkyl-heteroaryl and -C ₀ -C ₄ alkyl-heterocyclyl, wherein each alkyl, aryl, heteroaryl and heterocyclyl is optionally substituted with one or three substituents independently selected from the group consisting of halo, -OH, amino, -CN or -Ci-C ₄ alkyl; and

R ³ is independently selected from the group consisting of -H, alkyl, Co-C ₃ alkyl-heterocyclyl, Ci-C ₃ alkyl-C ₂ -C ₆ alkenyl, Ci-C ₃ alkyl-C ₂ -C ₃ alkynyl, -C ₂ -C ₄ alkyl-OR ¹ , -C ₂ -C ₄ alkyl-

NR ^3b R ^3c , -C ₂ -C ₄ alkyl-NR ¹ R ² , heteroalkyl, C ₀ -C ₆ alkylheteroaryl, C(O)CF ₃ , -C(O)-NH ₂ , -C(O)-NR ^3b R ^3c , -C(O)-NR ¹ R ² , -C(O)-OR ¹ , -S(O) ₂ -NR ¹ R ² , -S(O) ₂ -R ¹ , -C(O)-R ¹ , -C ₃ -

Cβcycloalkyl, -Co-Csalkyl-Cs-Cycycloalkyl, -Ci-Cβalkylaryl, aryl, Co-C ₃ alkyl-heteroaryl and heteroaryl, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl moiety is optionally substituted with from one to three independently selected substituents; wherein

R ¹ and R ² are independently selected from the group consisting of -H, Ci-Cβalkyl, aryl, heteroaryl, heterocyclyl, cycloalkyl and a protecting group; and wherein R ^3b and R ^3c , together with the atom to which they are attached, optionally form a heterocyclic ring, wherein the heterocyclyl moiety is optionally substituted.

70. The compound according to claim 69, wherein R ³ is R ¹⁸⁰ , wherein R ¹⁸⁰ is selected from the group consisting of H, -Ci-Cβalkyl, -Ci-Cβalkenyl, -Ci-Cβalkynyl, -C ₂ -Cealkoxyl, -C ₂ -C ₆ alkyl-O-R ⁵³ , -OR ⁵³ , -C ₂ -C ₆ alkyl-S(O) ₀ - ₂ -R ⁵³ , -C ₂ -C ₆ alkyl-C(O)-R ⁵³ , -C ₂ -C ₆ alkyl- C(O)NR ⁵⁰ R ⁵¹ , -C ₂ -C ₆ alkyl- NR ⁵² C(O)-R ⁵³ , -C ₂ -C ₆ alkyl-S(O) ₂ NR ⁵⁰ R ⁵¹ , -C ₂ -C ₆ alkyl- NR ⁵² S(O) ₂ -R ⁵³ , -C ₂ -C ₆ alkyl-OC(O)NR ⁵⁰ R ⁵¹ , -C ₂ -C ₆ alkyl- NR ⁵² C(O)O-R ⁵³ , -C ₂ -C ₆ alkyl- NR ⁵² C(O)NR ⁵⁰ R ⁵¹ , -C ₂ -C ₆ alkyl-C(O)O-R ⁵³ , -C ₂ -C ₆ alkyl-OC(O)-R ⁵³ , -C ₀ -C ₆ alkyl -heterocyclyl- R ⁵³ , -Co-Cealkyl-heterocyclyl-O-R ⁵³ , -C ₀ -C ₆ alkyl-heterocyclyl-S(O) ₀ - ₂ -R ⁵³ , -Co-C ₆ alkyl-heterocyclyl-C(0)-R ⁵³ , -Co-C ₆ alkyl-heterocyclyl-C(0)NR ⁵⁰ R ⁵¹ , -C ₀ -C ₆ alkyl- heterocyclyl-NR ⁵² C(O)-R ⁵³ , -C ₀ -C ₆ alkyl-heterocyclyl-S(O) ₂ NR ⁵⁰ R ⁵¹ , -C ₀ -C ₆ alkyl- heterocyclyl-NR ⁵² S(O) ₂ -R ⁵³ , -Co-C ₆ alkyl-heterocyclyl-OC(0)NR ⁵ °R ⁵¹ , -Co-C ₆ alkyl- heterocyclyl-NR ⁵² C(O)O-R ⁵³ , -Co-C ₆ alkyl-heterocyclyl-NR ⁵² C(0)NR ⁵ °R ⁵¹ , -Co-C ₆ alkyl- heterocyclyl-C(O)O-R ⁵³ , -C ₀ -C ₆ alkyl-heterocyclyl-OC(O)-R ⁵³ , -C ₀ -C ₆ alkyl -cycloalkyl- R ⁵³ , -Co-C ₆ alkyl- cycloalkyl -O-R ⁵³ , -C ₀ -C ₆ alkyl- cycloalkyl -S(O) _0-2 -R ⁵³ , -C ₀ -C ₆ alkyl- cycloalkyl-C(O)-R ⁵³ , -C ₀ -C ₆ alkyl- cycloalkyl -C(O)NR ⁵⁰ R ⁵¹ , -C ₀ -C ₆ alkyl- cycloalkyl- NR ⁵² C(O)-R ⁵³ , -Co-C ₆ alkyl- cycloalkyl-S(O) ₂ NR ⁵⁰ R ⁵¹ , -C ₀ -C ₆ alkyl- cycloalkyl-NR ⁵² S(O) ₂ - R ⁵³ , -Co-C ₆ alkyl- cycloalkyl-OC(O)NR ⁵⁰ R ⁵¹ , -C ₀ -C ₆ alkyl- cycloalkyl-NR ⁵² C(O)O-R ⁵³ , -C ₀ - C ₆ alkyl- cycloalkyl-NR ⁵² C(O)NR ⁵⁰ R ⁵¹ , -C ₀ -C ₆ alkyl- cycloalkyl-C(O)O-R ⁵³ , -C ₀ -C ₆ alkyl- cycloalkyl-OC(O)-R ⁵³ , -C ₀ -C ₆ alkyl -heteroaryl- R ⁵³ , -C ₀ -C ₆ alkyl- heteroaryl -O-R ⁵³ , -C ₀ - C ₆ alkyl- heteroaryl -S(O) _0-2 -R ⁵³ , -C ₀ -C ₆ alkyl- heteroaryl -C(O)-R ⁵³ , -C ₀ -C ₆ alkyl- heteroaryl -C(O)NR ⁵⁰ R ⁵¹ , -C ₀ -C ₆ alkyl- heteroaryl -NR ⁵² C(O)-R ⁵³ , -C ₀ -C ₆ alkyl- heteroaryl -S(O) ₂ NR ⁵⁰ R ⁵¹ , -C ₀ -C ₆ alkyl- heteroaryl -NR ⁵² S(O) ₂ -R ⁵³ , -C ₀ -C ₆ alkyl- heteroaryl -OC(O)NR ⁵⁰ R ⁵¹ , -C ₀ -C ₆ alkyl- heteroaryl-NR ⁵² C(O)O-R ⁵³ , -C ₀ -C ₆ alkyl- heteroaryl -NR ⁵² C(O)NR ⁵⁰ R ⁵¹ , -C ₀ -C ₆ alkyl- heteroaryl -C(O)O-R ⁵³ , -C ₀ -C ₆ alkyl- heteroaryl -OC(O)-

R ⁵³ , -Co-C ₆ alkyl -aryl- R ⁵³ , -C ₀ -C ₆ alkyl- aryl -O-R ⁵³ , -C ₀ -C ₆ alkyl- aryl -S(O) ₀ - ₂ -R ⁵³ , -C ₀ - C ₆ alkyl- aryl -C(O)-R ⁵³ , -C ₀ -C ₆ alkyl-aryl -C(O)NR ⁵⁰ R ⁵¹ , -C ₀ -C ₆ alkyl-aryl -NR ⁵² C(O)-R ⁵³ , -Co-C ₆ alkyl- aryl -S(O) ₂ NR ⁵⁰ R ⁵¹ , -C ₀ -C ₆ alkyl-aryl -NR ⁵² S(O) ₂ -R ⁵³ , -C ₀ -C ₆ alkyl-aryl -OC(O)NR ⁵⁰ R ⁵¹ , -Co-C ₆ alkyl-aryl-NR ⁵² C(0)0-R ⁵³ , -C ₀ -C ₆ alkyl-aryl -NR ⁵² C(O)NR ⁵⁰ R ⁵¹ , -Co-Cealkyl-aryl -C(O)O-R ⁵³ , -C ₀ -C ₆ alkyl-aryl -OC(O)-R ⁵³ , -C ₀ -C ₆ alkyl-aryl, -C ₀ -C ₆ alkyl- heteroaryl, -Co-Cealkyl-cycloalkyl, -Co-Cealkyl-heterocyclyl and -C ₂ -C ₆ alkyl-NR ⁵⁰ R ⁵¹ , wherein each alkyl and heteroalkyl is optionally substituted with one to three substituents independently selected from the group consisting of F, -OH and oxo, wherein each aryl, heteroaryl, cycloalkyl and heterocyclyl is optionally substituted with one or two substituents.

71. A compound selected from the group consisting of:

(Z)-4-(dibenzo[b,f] [ 1 ,4]oxazepin- 11 -yl)-N-hydroxybenzamide,

(Z)-4-(dibenzo[b,f] [ 1 ,4]thiazepin- 11 -yl)-N-hydroxybenzamide,

4-(l 0, 11 -dihydrodibenzo[b,f] [1 ,4]oxazepin- 11 -yl)-N-hydroxybenzamide,

N-hydroxy-4-( 10-methyl- 10,11 -dihydrodibenzo[b,fj [ 1 ,4]oxazepin- 11 -yl)benzamide,

(Z)-4-(8-chloro-5H-dibenzo[b,e][l,4]diazepin-l l-yl)-N-hydroxybenzamide,

(Z)-4-(benzo[b]pyrido[3,2-fJ[l,4]oxazepin-5-yl)-N-hydroxybenzamide,

(Z)-4-(2-fluorodibenzo[b,fJ[l,4]oxazepin-l l-yl)-N-hydroxybenzamide,

(Z)-N-hydroxy-4-(2-methoxydibenzo[b,f][l,4]oxazepin-l l-yl)benzamide,

(Z)-4-(benzo[b]pyrido[4,3-fJ [ 1 ,4]oxazepin-5-yl)-N-hydroxybenzamide,

(Z)-4-(2-(2-(dimethylamino)ethoxy)dibenzo[b,f][l,4]oxazepin-l l-yl)-N-hydroxybenzamide,

(Z)-N-hydroxy-4-(8-(trifluoromethyl)dibenzo[b,fJ[l,4]oxazepin-l l-yl)benzamide,

(Z)-4-(dibenzo[b,f][l,4]oxazepin-l l-yl)-2-fluoro-N-hydroxybenzamide,

(Z)-5-(4-(hydroxycarbamoyl)phenyl)benzo[b]pyrido[4,3-f][l,4]oxazepine 2-oxide,

(Z)-N-hydroxy-4-(3-methoxydibenzo[b,f][l,4]oxazepin-l l-yl)benzamide,

(Z)-3-(dibenzo[b,f] [1 ,4]oxazepin- 11 -yl)-N-hydroxybenzamide,

(Z)-N-hydroxy-4-(8-methyldibenzo[b,fJ[l,4]oxazepin-l l-yl)benzamide,

(Z)-N-hydroxy-4-(4-methoxydibenzo[b,f][l,4]oxazepin-l l-yl)benzamide,

(Z)-4-(9-fluorodibenzo[b,fJ[l,4]oxazepin-l l-yl)-N-hydroxybenzamide,

(Z)-N-hydroxy-4-(7-(trifluoromethyl)dibenzo[b,fJ[l,4]oxazepin-l l-yl)benzamide,

(Z)-4-(7-chlorodibenzo[b,f][l,4]oxazepin-l l-yl)-N-hydroxybenzamide,

(Z)-4-(2-chlorodibenzo[b,f][l,4]oxazepin-l l-yl)-N-hydroxybenzamide,

(Z)-4-(8-cyanodibenzo[b,f][l,4]oxazepin-l l-yl)-N-hydroxybenzamide,

(Z)-N-hydroxy-4-(4-methyldibenzo[b,fJ[l,4]oxazepin-l l-yl)benzamide,

(Z)-N-hydroxy-4-(3-methyldibenzo[b,f][l,4]oxazepin-l l-yl)benzamide,

(Z)-4-(benzo[b]thieno[2,3-f][l,4]oxazepin-10-yl)-N-hydroxybenzamide,

(Z)-4-(3-fluorodibenzo[b,f][l,4]oxazepin-l l-yl)-N-hydroxybenzamide,

(Z)-4-(8-chlorodibenzo[b,f][l,4]oxazepin-l l-yl)-N-hydroxybenzamide,

(Z)-N-hydroxy-4-(3-(trifluoromethyl)dibenzo[b,f][l,4]oxazepin-l l-yl)benzamide,

(Z)-4-(6-fluorodibenzo[b,f][l,4]oxazepin-l l-yl)-N-hydroxybenzamide,

(Z)-4-(7-cyanodibenzo[b,f][l,4]oxazepin-l l-yl)-N-hydroxybenzamide,

(Z)-N-hydroxy-4-(4-hydroxydibenzo[b,f][l,4]oxazepin-l l-yl)benzamide,

(Z)-N-hydroxy-4-( 1 -methoxydibenzo[b,f] [ 1 ,4]oxazepin- 11 -yl)benzamide,

(Z)-N-hydroxy-4-(4-(2-methoxyethoxy)dibenzo[b,f][l,4]oxazepin-l l-yl)benzamide,

(Z)-4-( 1 -fluorodibenzo[b,f] [ 1 ,4]oxazepin- 11 -yl)-N-hydroxybenzamide,

(Z)-N-hydroxy-4-(2-(trifluoromethyl)benzo[f]pyrido[2,3-b][l,4]oxazepin-6-yl)benzamide,

(Z)-4-(l l-cyclopropyl-l lH-benzo[b]pyrido[2,3-e][l,4]diazepin-5-yl)-N-hydroxybenzamide,

(Z)-4-(5-cyclopropyl-5H-dibenzo[b,e][l,4]diazepin-l l-yl)-N-hydroxybenzamide,

(Z)-4-(5H-dibenzo[b,e] [ 1 ,4]diazepin- 11 -yl)-N-hydroxybenzamide,

(Z)-N-hydroxy-4-(4-(2-morpholinoethoxy)dibenzo[b,f] [ 1 ,4]oxazepin- 11 -yl)benzamide,

(Z)-4-(benzo[f]pyrido[2,3-b] [ 1 ,4]oxazepin-6-yl)-N-hydroxybenzamide,

(Z)-4-(2-fluoro-4-methoxydibenzo[b,f][l,4]oxazepin-l l-yl)-N-hydroxybenzamide,

(Z)-N-hydroxy-4-(4-(methylthio)dibenzo[b,f][l,4]oxazepin-l l-yl)benzamide,

(Z)-N-hydroxy-4-(4-(trifluoromethyl)dibenzo[b,f][l,4]oxazepin-l l-yl)benzamide,

(Z)-N-hydroxy-4-(4-(methylsulfÏŠnyl)dibenzo[b,f][l,4]oxazepin-l l-yl)benzamide,

(Z)-4-(5H-benzo[e]pyrrolo[ 1 ,2-a] [1 ,4]diazepin- 11 -yl)-N-hydroxybenzamide,

(Z)-N-hydroxy-4-(4-(methylsulfonyl)dibenzo[b,f][l,4]oxazepin-l l-yl)benzamide,

(E)-4-((dibenzo[b,f][l,4]oxazepin-l l-ylamino)methyl)-N-hydroxybenzamide,

(Z)-N-hydroxy-4-(4-methoxy-8-(trifluoromethyl)dibenzo[b,f][l,4]oxazepin-l l-yl)benzamide,

(Z)-N-hydroxy-4-(3-morpholinodibenzo[b,f] [ 1 ,4]oxazepin- 11 -yl)benzamide,

(Z)-N-hydroxy-4-(4-propyldibenzo[b,f][l,4]oxazepin-l l-yl)benzamide,

(Z)-N-hydroxy-4-(4-(trifluoromethoxy)dibenzo[b,f][l,4]oxazepin-l l-yl)benzamide,

(Z)-N-hydroxy-4-(6-methyldibenzo[b,f][l,4]oxazepin-l l-yl)benzamide,

(E)-4-(dibenzo[b,f][l,4]oxazepin-l l-yl)-3-fluoro-N-hydroxybenzamide,

(E)-β-(dibenzo [b,f] [ 1 ,4]oxazepin- 11 -yl)-N-hydroxynicotinamide,

(E)-5-(dibenzo[b,f][l,4]oxazepin-l l-yl)-N-hydroxyfuran-2-carboxamide,

(E)-5-(dibenzo[b,f][l,4]oxazepin-l l-yl)-N-hydroxythiophene-2-carboxamide,

(Z)-4-(5-ethyl-5H-dibenzo[b,e][l,4]diazepin-l l-yl)-N-hydroxybenzamide,

(Z)-4-(5-cyclopropyl-5H-dibenzo[b,e] [ 1 ,4]diazepin- 11 -yl)-N-hydroxy-N-methylbenzamide,

(Z)-N-hydroxy-4-(5-isopropyl-5H-dibenzo[b,e][l,4]diazepin-l l-yl)benzamide,

(E)-4-((5-cyclopropyl-5H-dibenzo[b,e][l,4]diazepin-l l-ylamino)methyl)-N- hydroxybenzamide,

(Z)-4-(4-fluorodibenzo[b,f][l,4]oxazepin-l l-yl)-N-hydroxybenzamide,

(Z)-N-hydroxy-4-(5-(2-methoxyethyl)-5H-dibenzo[b,e][l,4]diazepin-l l-yl)benzamide,

(E)-4-(2-(dibenzo[b,f][l,4]oxazepin-l l-ylamino)ethyl)-N-hydroxybenzamide,

(Z)-4-(l l-ethyl-l lH-benzo[b]pyrido[2,3-e][l,4]diazepin-5-yl)-N-hydroxybenzamide,

(Z)-4-(5-cyclopropyl-2-fluoro-5H-dibenzo[b,e][l,4]diazepin-l l-yl)-N-hydroxybenzamide,

(Z)-N-hydroxy-4-(l l-isopropyl-l lH-benzo[b]pyrido[2,3-e][l,4]diazepin-5-yl)benzamide,

(Z)-4-(benzo[f]thieno[2,3-b][l,4]oxazepin-5-yl)-N-hydroxybenzamide,

(Z)-6-(4-(dibenzo[b,f][l,4]oxazepin-l l-yl)benzamidooxy)-3,4,5-trihydroxytetrahydro-2H- pyran-2-carboxylic acid,

(Z)-N-hydroxy-4-(l l-(3-morpholinopropyl)-l lH-benzo[b]pyrido[2,3-e][l,4]diazepin-5- yl)benzamide,

(Z)-N-hydroxy-4-(l l-(2-morpholinoethyl)-l lH-benzo[b]pyrido[2,3-e][l,4]diazepin-5- yl)benzamide,

(Z)-4-(l l-(cyclopropylmethyl)-l lH-benzo[b]pyrido[2,3-e][l,4]diazepin-5-yl)-N- hydroxybenzamide,

(Z)-N-hydroxy-4-(5-(2-morpholinoethyl)-5H-dibenzo[b,e][l,4]diazepin-l l-yl)benzamide,

72. A compound represented by the Formula VIII:

and N-oxides, hydrates, solvates, pharmaceutically acceptable salts, prodrugs, polymorphs and complexes thereof, and racemic and scalemic mixtures, diastereomers and enantiomers thereof, wherein

R ⁴ is independently selected from the group consisting of -H, Ci-C ₆ alkyl, C ₂ -Cealkenyl, C ₂ - C ₆ alkynyl, Ci-C ₆ alkyl-R ³ , -C ₀ -C ₆ alkyl-OR ³ , -Co-Cealkyl-OR ¹ , -C ₀ -C ₆ alkyl-C(O)-OR ³ , -Co-C ₆ alkyl-C(0)NR ³ R ^3a , -CH=CH-C(O)-OR ³ , -CH=CH-C(O)-N(R ³ )(R ^3a ), -N(R ³ )- C(O)-CF ³ , -N(R ³ )-C ₂ -C ₆ alkyl-N(R ³ )(R ^3a ), -C ₀ -C ₆ alkyl-N(R ³ )(R ^3a ), -N(R ³ )-C(O)-C _r C ₆ alkyl-R ³ , -N(R ³ )-S(O) ₂ -Ci-C ₆ alkyl-R ³ , - S(O) ₂ -N(R ³ )R ^3a , -O-C ₂ -C ₆ alkyl-N(R ³ )(R ^3a ), -O-Cz-Cealkyl-OR ¹ , -S-R ³ , -S(O)-Ci-C ₆ alkyl-R ³ , -S(O) ₂ -Ci-C ₆ alkyl-R ³ , C ₃ -C ₆ cycloalkyl, heterocyclyl, C4-Cyheterocyclyl-R ³ , -O-C ₂ -C4alkyl-heterocyclyl, -O-heterocyclyl-C(O)- OR ³ , -0-Co-C ₄ alkyl-aryl, -O-C ₀ -C ₄ alkyl-heteroaryl, -O-C(O)-NR ³ -C ₀ -C ₄ alkyl-aryl, -O- C(O)-NR ³ -C ₀ -C ₄ alkyl-heteroaryl, -0-Co-C ₄ alkyl-heterocyclylaryl, -O-C ₀ -C ₄ alkyl- heterocyclyl-heteroaryl, -N(R ³ )-C ₂ -C ₄ alkyl-heterocyclyl, -N(R ³ )C(O)N(R ³ )-C ₀ -C ₄ alkyl- heterocyclyl-R ³ , -C ₀ -C ₄ alkyl-OC(O)-R ³ , -C ₀ -C ₄ alkyl-N(R ³ )C(O)-O-R ³ , -C ₀ -C ₄ alkyl- heterocyclyl-C(O)-O-R ³ , -N(R ³ )-C ₂ -C ₄ alkyl-heterocyclyl, F, Cl, Br, I, NO ₂ , -CF ₃ , -OCF ₃ , -OCHF ₂ , -SCF ₃ , -SF ₅₅ -SO ₃ H, -CN, -Ci-C ₆ alkylaryl, aryl, heteroaryl, cycloalkyl, -Ci-C ₆ alkylheteroaryl, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl moeity of the aformentioned R ⁴ is optionally substituted; each A is independently selected from the group consisting of N, -N-oxide, -CH= and -C(R ⁴ )=, wherein no more than two A per 5 or 6 membered ring are N, and wherein no more than one A is -N-oxide;

Z is -N(R ¹ PR ² or H;

L is a covalent bond or -C ₀ -C ₃ alkyl-N(OR ² )-; wherein, when L is C ₀ -C ₃ alkyl-N(OR ² )-, then Z is H; and wherein, when Z is H, then L is -C ₀ -C ₃ alkyl-N(OR ² )-;

G ² is carbon or N;

U ² is selected from the group consisting of a covalent bond, -Ci-C ₈ alkyl-, -C(R ³⁰⁰ )(R ⁴⁰⁰ )-, -C(O)-C(R ³⁰¹ )(R ⁴⁰¹ )-, -Co-C ₂ alkyl-C(0)-0-C ₀ -C ₄ alkyl-,-Co-C ₂ alkyl-C(0)-Co-C ₄ alkyl-,-

Co-C ₂ alkyl-C(0)-NR -Co-C ₄ alkyl-, -C(0)-0-C(R ⁱ⁰¹ )(R ⁴⁰¹ )-, -C(O)-C(R ⁱ⁰¹ )(R ⁴⁰¹ )- and -C(O)-NR ³ -C(R ³⁰⁰ )(R ⁴⁰⁰ )-, each R ³ is independently selected from the group consisting of -H, alkyl, Co-C ₃ alkyl- heterocyclyl, Ci-C ₃ alkyl-C ₂ -C ₆ alkenyl, d-C ₃ alkyl-C ₂ -C ₃ alkynyl, -C ₂ -C ₄ alkyl-OR ¹ , -C ₂ - C ₄ alkyl-NR ^3b R ^3c , -C ₂ -C ₄ alkyl-NR ¹ R ² , heteroalkyl, C ₀ -C ₆ alkylheteroaryl, C(O)CF ₃ , -C(O)-NH ₂ , -C(O)-NR ^3b R ^3c , -C(O)-NR ¹ R ² , -C(O)-OR ¹ , -S(O) ₂ -NR ¹ R ² , -S(O) ₂ -R ¹ , -C(O)- R ¹ , -C ₃ -C ₆ CVClOaIkVl, -C ₀ -C ₃ alkyl-C ₃ -C ₇ cycloalkyl, -Ci-C ₆ alkylaryl, aryl, C ₀ -C ₃ alkyl-

heteroaryl and heteroaryl, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl moiety is optionally substituted with from one to three independently selected substituents; each R ^3a is independently selected from the group consisting of -H, alkyl, heterocyclyl, C ₂ - Cβalkenyl, C ₂ -C ₃ alkynyl, C^Qalkyl-OR ¹ , heteroalkyl, heteroaryl, Co-Cβalkylheteroaryl, C(O)CF ₃ , -C(O)-NH ₂ , -Cs-Cecycloalkyl, -alkyl-Cs-Cecycloalkyl, -Ci-C ₆ alkylaryl, aryl, alkylheteroaryl and heteroaryl, covalent bond, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl moiety is optionally substituted; wherein R ³ and R ^3a , together with the atom to which they are attached, optionally form a heterocyclic ring, wherein the heterocyclyl moiety is optionally substituted;

R ³⁰⁰ and R ⁴⁰⁰ are independently selected from the group consisting of -H, -F, -Ci-Cβalkyl, aryl, heteroaryl, heterocyclyl and cycloalkyl;

R ³⁰¹ and R ⁴⁰¹ are independently selected from the group consisting of -H, F, OR ¹ , -NR ³ R ^3a -, -Ci-Cβalkyl, aryl, heteroaryl, heterocyclyl and cycloalkyl;

_R ² oo _{^ R} ² o ⁱ _{^ R} ²⁰² _{and R} ²⁰³ _&χQ independently selected from the group consisting of -H, -Ci- Cβalkyl, aryl, heteroaryl, heterocyclyl and cycloalkyl; and

selected from the group consisting of hydrogen, aryl, heteroaryl, alkyl, heterocyclyl, cycloalkyl, wherein each aryl, heteroaryl, cycloalkyl and heterocyclyl is optionally substituted with one to three substituents independently selected from the group consisting of halo, -CF ₃ , -OCF ₃ , -SCF ₃ , -SF ₅ , -NO ₂ , -CN, -Ci-C ₆ alkyl, -Ci-C ₆ alkoxyl, -0-C ₂ - Cealkyl-O-R ¹ , -0-R ¹ , -OCF ₂ H, -C ₀ -C ₆ alkyl-S(O) ₀ .2-R ¹ , -C ₀ -C ₆ alkyl-C(O)-R ¹ , -C ₀ -C ₆ alkyl- C(O)NR ³ R ^3a , -C ₀ -C ₆ alkyl- NR ³ C(O)-R ² , -C ₀ -C ₆ alkyl-S(O) ₂ NR ³ R ^3a , -C ₀ -C ₆ alkyl- NR ³ S(O) ₂ - R ² , -Co-C ₆ alkyl-OC(0)NR ³ R ^3a , -C ₀ -C ₆ alkyl- NR ³ C(O)O-R ¹ , -C ₀ -C ₆ alkyl- NR ¹ C(O)NR ³ R ³ ", -Co-C ₆ alkyl-C(0)0-R ¹ , -C ₀ -C ₆ alkyl-OC(O)-R ¹ , -C ₀ -C ₆ alkyl-aryl, -Co-Cealkyl-heteroaryl, -C ₀ - C ₆ alkyl-C ₃ -C ₇ cycloalkyl, -C ₀ -C ₆ alkyl-heterocyclyl, -C ₀ -C ₆ alkyl-NR ³ R ^3a and -O-C ₂ -C ₆ alkyl- NR ³ R ^3a ; and

R ¹ and R ² are independently selected from the group consisting of -H, Ci-Cβalkyl, aryl, heteroaryl, heterocyclyl, cycloalkyl and a protecting group.

73. The compound according to claim 72, wherein the moiety

74. The compound according to claim 72, wherein the moiety

75. The compound according to any of claims 72 to 74, wherein the moiety

is a radical selected from the group consisting of

and

76. The compound according to any of claims 72 to 75, wherein the moiety

is a radical selected from the group consisting of

or an enantiomer thereof, a scalemic thereof, or a mixture of enantiomers thereof.

77. The compound according to any of claims 72 to 76, wherein U ² is a covalent bond.

78. The compound according to any of claims 72 to 76, wherein U ² is selected from the group consisting of a -Ci-C ₄ alkyl, -CH(aryl)-, -CH(heteroaryl)-, -C(O)-, -C(O)-CH(aryl)-, -C(O)-CH(heteroaryl)-, -C(O)O- Ci-C ₂ alkyl-, -C(O)O- and -C(O)NH-.

79. The compound according to any of claims 72 to 78, wherein the moiety

is a radical selected from the group consisting of H, alkyl, aryl, heteroaryl, cycloalkyl and heterocyclyl, wherein each aryl, heteroaryl, cycloalkyl and heterocyclyl is optionally substituted with one to three substituents independently selected from the group

consisting of halo, -CF ₃ , -OCF ₃ , -SCF ₃ , -SF ₅ , -CN, -Ci-C ₆ alkyl, -O-C ₂ -C ₆ alkyl-O-R ¹ , -O-R ¹ , -OCF ₂ H, -Co-C ₆ alkyl-S(0)o-2-R ¹ , -C ₀ -C ₆ alkyl-C(O)NR ³ R ^3a , -C ₀ -C ₆ alkyl- NR ³ C(O)-R ² , -C ₀ - C ₆ alkyl-S(O) ₂ NR ³ R ^3a , -C ₀ -C ₆ alkyl- NR ³ S(O) ₂ -R ² , -C ₀ -C ₆ alkyl-OC(O)NR ³ R ^3a , -C ₀ -C ₆ alkyl- NR ³ C(O)O-R ¹ , -C ₀ -C ₆ alkyl- NR ¹ C(O)NR ³ R ³ ", -C ₀ -C ₆ alkyl-C(O)O-R ¹ , -C ₀ -C ₆ alkyl-OC(O)- R ¹ , -Co-C ₆ alkyl-aryl, -Co-Cealkyl-heteroaryl, -C ₀ -C ₆ alkyl-C ₃ -C ₇ cycloalkyl, -C ₀ -C ₆ alkyl- heterocyclyl, -C ₀ -C ₆ alkyl-NR ³ R ^3a and -O-C ₂ -C ₆ alkyl-NR ³ R ^3a .

80. The compound according to any of claims 72 to 78, wherein the moiety

is a radical selected from the group consisting of

81. The compound according to claim 72, represented by the Formula (IX):

or where possible, a (R,R) or (S, S) enantiomer, scalemic or a mixture of enantiomers thereof.

82. The compound according to claim 72, represented by the Formula (X):

(X) or where possible, a (R,R) or (S, S) enantiomer, scalemic or a mixture of enantiomers thereof.

83. The compound according to claim 72, wherein the moiety

a radical selected from the group consisting of

84. A compound selected from the group consisting of:

2-((lS,4S)-5-benzyl-2,5-diazabicyclo[2.2.1]heptan-2-yl)-N-hydroxypyrimidine-5- carboxamide,

N-hydroxy-2-(( 1 S ,4S)-5 -p-tolyl-2,5 -diazabicyclo [2.2.1 ]heptan-2-yl)pyrimidine-5 - carboxamide,

2-((lS,4S)-5-benzhydryl-2,5-diazabicyclo[2.2.1]heptan-2-yl)-N-hydroxypyrimidine-5- carboxamide,

2-((lS,4S)-5-(4-chlorophenyl)-2,5-diazabicyclo[2.2.1]heptan-2-yl)-N-hydroxypyrimidine-5- carboxamide,

( 1 S,4S)-tert-butyl 5 -(5 -(hydroxycarbamoyl)pyrimidin-2-yl)-2 ,5 -diazabicyclo [2.2.1 Jheptane-

2-carboxylate,

2-((lS,4S)-5-(3-fluorophenyl)-2,5-diazabicyclo[2.2.1]heptan-2-yl)-N-hydroxypyrimidine-5- carboxamide,

2-((lS,4S)-5-(4-fluorophenyl)-2,5-diazabicyclo[2.2.1]heptan-2-yl)-N-hydroxypyrimidine-5- carboxamide,

2-((lS,4S)-2,5-diazabicyclo[2.2.1]heptan-2-yl)-N-hydroxypyrimidine-5-carboxamide,

N-hydroxy-2-(( 1 S ,4S)-5 -o-tolyl-2,5 -diazabicyclo [2.2.1 ]heptan-2-yl)pyrimidine-5 - carboxamide,

N-hydroxy-2-((l S,4S)-5-phenyl-2,5-diazabicyclo[2.2.1 ]heptan-2-yl)pyrimidine-5- carboxamide,

2-((lS,4S)-5-benzoyl-2,5-diazabicyclo[2.2.1]heptan-2-yl)-N-hydroxypyrimidine-5- carboxamide,

N-hydroxy-2-((l S,4S)-5-(3-(trifluoromethyl)phenyl)-2,5-diazabicyclo[2.2.1 ]heptan-2- yl)pyrimidine-5 -carboxamide,

2-((lS,4S)-5-(2-fluoro-4-(trifluoromethyl)phenyl)-2,5-diazabicyclo[2.2.1]heptan-2-yl)-N- hydroxypyrimidine-5 -carboxamide,

N-hydroxy-2-((lS,4S)-5-(2-(trifluoromethyl)phenyl)-2,5-diazabicyclo[2.2.1]heptan-2- yl)pyrimidine-5 -carboxamide,

N-hydroxy-2-((l S,4S)-5-(4-(trifluoromethyl)phenyl)-2,5-diazabicyclo[2.2.1 ]heptan-2- yl)pyrimidine-5 -carboxamide,

2-((lS,4S)-5-(benzo[c][l,2,5]oxadiazol-5-yl)-2,5-diazabicyclo[2.2.1]heptan-2-yl)-N- hydroxypyrimidine-5 -carboxamide,

2-((lS,4S)-5-(benzo[c][l,2,5]thiadiazol-5-yl)-2,5-diazabicyclo[2.2.1]heptan-2-yl)-N- hydroxypyrimidine-5 -carboxamide,

N-hydroxy-2-((l S,4S)-5-(3-(trifluoromethyl)benzoyl)-2,5-diazabicyclo[2.2.1 ]heptan-2- yl)pyrimidine-5 -carboxamide,

2-((lS,4S)-5-(benzo[d][l,3]dioxol-5-yl)-2,5-diazabicyclo[2.2.1]heptan-2-yl)-N- hydroxypyrimidine-5 -carboxamide,

2-((lS,4S)-5-(cyclohexanecarbonyl)-2,5-diazabicyclo[2.2.1]heptan-2-yl)-N- hydroxypyrimidine-5 -carboxamide,

2-((lS,4S)-5-(2,2-diphenylacetyl)-2,5-diazabicyclo[2.2.1]heptan-2-yl)-N-hydroxypyrimidine-

5 -carboxamide,

N-hydroxy-4-((lS,4S)-5-p-tolyl-2,5-diazabicyclo[2.2.1]heptan-2-yl)benzamide,

(lS,4S)-benzyl 5-(5-(hydroxycarbamoyl)pyrimidin-2-yl)-2,5-diazabicyclo[2.2.1]heptane-2- carboxylate,

(lS,4S)-isobutyl 5-(5-(hydroxycarbamoyl)pyrimidin-2-yl)-2,5-diazabicyclo[2.2.1]heptane-2- carboxylate,

N-hydroxy-2-((l S,4S)-5-(3-(trifluoromethoxy)phenyl)-2,5-diazabicyclo[2.2.1 ]heptan-2- yl)pyrimidine-5 -carboxamide,

2-((lS,4S)-5-(2,2-difluorobenzo[d][l,3]dioxol-5-yl)-2,5-diazabicyclo[2.2.1]heptan-2-yl)-N- hydroxypyrimidine-5 -carboxamide,

N-hydroxy-2-((l S,4S)-5-(3-(trifluoromethylthio)phenyl)-2,5-diazabicyclo[2.2.1 ]heptan-2- yl)pyrimidine-5 -carboxamide,

N-hydroxy-2-((l S,4S)-5-(4-(trifluoromethyl)pyridin-2-yl)-2,5-diazabicyclo[2.2.1 ]heptan-2- yl)pyrimidine-5 -carboxamide,

N-hydroxy-2-((l S,4S)-5-(2-(trifluoromethyl)quinolin-4-yl)-2,5-diazabicyclo[2.2.1 ]heptan-2- yl)pyrimidine-5 -carboxamide,

2-((lS,4S)-5-(3-(difluoromethoxy)phenyl)-2,5-diazabicyclo[2.2.1]heptan-2-yl)-N- hydroxypyrimidine-5 -carboxamide,

N-hydroxy-2-((lS,4S)-5-(6-(trifluoromethyl)pyridin-2-yl)-2,5-diazabicyclo[2.2.1]heptan-2- yl)pyrimidine-5 -carboxamide,

(1 S,4S)-cyclopentyl 5-(5-(hydroxycarbamoyl)pyrimidin-2-yl)-2,5- diazabicyclo[2.2.1 ]heptane-2-carboxylate,

2-((lS,4S)-5-(benzo[c][l,2,5]oxadiazol-4-yl)-2,5-diazabicyclo[2.2.1]heptan-2-yl)-N- hydroxypyrimidine-5 -carboxamide,

N-hydroxy-2-((lS,4S)-5-(5-(trifluoromethyl)pyridin-3-yl)-2,5-diazabicyclo[2.2.1]heptan-2- yl)pyrimidine-5 -carboxamide,

N-hydroxy-2-((lR,4R)-5-p-tolyl-2,5-diazabicyclo[2.2.1]heptan-2-yl)pyrimidine-5- carboxamide,

(lS,4S)-isopropyl 5-(5-(hydroxycarbamoyl)pyrimidin-2-yl)-2,5-diazabicyclo[2.2.1]heptane-

2-carboxylate,

(lS,4S)-pyridin-3-ylmethyl 5-(5-(hydroxycarbamoyl)pyrimidin-2-yl)-2,5- diazabicyclo[2.2.1 ]heptane-2-carboxylate,

(lS,4S)-cyclopropylmethyl 5-(5-(hydroxycarbamoyl)pyrimidin-2-yl)-2,5- diazabicyclo[2.2.1 ]heptane-2-carboxylate,

(lS,4S)-tetrahydro-2H-pyran-4-yl 5-(5-(hydroxycarbamoyl)pyrimidin-2-yl)-2,5- diazabicyclo[2.2.1 ]heptane-2-carboxylate,

2-((lS,4S)-5-(3,5-bis(trifluoromethyl)phenyl)-2,5-diazabicyclo[2.2.1]heptan-2-yl)-N- hydroxypyrimidine-5 -carboxamide,

2-(( 1 S ,4S)-5 -(benzo [d]isoxazol-3 -yl)-2,5 -diazabicyclo [2.2.1 ]heptan-2-yl)-N- hydroxypyrimidine-5 -carboxamide,

2-((lS,4S)-5-(3-(dimethylcarbamoyl)phenyl)-2,5-diazabicyclo[2.2.1]heptan-2-yl)-N- hydroxypyrimidine-5 -carboxamide,

2-((lS,4S)-5-(3-((dimethylamino)methyl)phenyl)-2,5-diazabicyclo[2.2.1]heptan-2-yl)-N- hydroxypyrimidine-5 -carboxamide,

N-hydroxy-2-((lS,4S)-5-(3-methoxyphenyl)-2,5-diazabicyclo[2.2.1]heptan-2-yl)pyrimidine-

5 -carboxamide,

N-hydroxy-2-((lS,4S)-5-m-tolyl-2,5-diazabicyclo[2.2.1]heptan-2-yl)pyrimidine-5- carboxamide,

N-hydroxy-6-(5-p-tolyl-2,5-diazabicyclo[2.2.1]heptan-2-yl)nicotinamide,

N-hydroxy-5-((l S,4S)-5-(3-(trifluoromethyl)phenyl)-2,5-diazabicyclo[2.2.1 ]heptan-2- yl)pyrazine-2-carboxamide,

2-fluoro-N-hydroxy-4-((l S,4S)-5-(3-(trifluoromethyl)phenyl)-2,5-diazabicyclo[2.2.1 ]heptan-

2-yl)benzamide,

N-hydroxy-2-((l S,4S)-5-(pyrrolidine- 1 -carbonyl)-2,5-diazabicyclo[2.2.1 ]heptan-2- yl)pyrimidine-5 -carboxamide,

N-hydroxy-2-((l S,4S)-5-(4-(trifluoromethyl)pyrimidin-2-yl)-2,5-diazabicyclo[2.2.1 Jheptan-

2-yl)pyrimidine-5 -carboxamide,

N-hydroxy-6-((l S,4S)-5-(3-(trifluoromethyl)phenyl)-2,5-diazabicyclo[2.2.1 ]heptan-2- yl)pyridazine-3 -carboxamide,

N-hydroxy-2-((lR,4R)-5-(4-(trifluoromethyl)pyridin-2-yl)-2,5-diazabicyclo[2.2.1]heptan-2- yl)pyrimidine-5 -carboxamide,

N-hydroxy-2-(( 1 R,4R)-5 -m-tolyl-2,5 -diazabicyclo [2.2.1 ]heptan-2-yl)pyrimidine-5 - carboxamide,

2-(5-(3-cyanophenyl)-2,5-diazabicyclo[2.2.1]heptan-2-yl)-N-hydroxypyrimidine-5- carboxamide,

N-hydroxy-4-(5-(3-methoxyphenyl)-2,5-diazabicyclo[2.2.1]heptan-2-yl)benzamide,

N-hydroxy-4-(5-m-tolyl-2,5-diazabicyclo[2.2.1]heptan-2-yl)benzamide,

N-hydroxy-4-((l S,4S)-5-(3-(trifluoromethyl)phenyl)-2,5-diazabicyclo[2.2.1 ]heptan-2- yl)benzamide,

N-hydroxy-4-((l S,4S)-5-(4-(trifluoromethyl)pyridin-2-yl)-2,5-diazabicyclo[2.2.1 ]heptan-2- yl)benzamide,

4-((lS,4S)-5-(3-cyanophenyl)-2,5-diazabicyclo[2.2.1]heptan-2-yl)-N-hydroxybenzamide,

N-hydroxy-4-((lR,4R)-5-m-tolyl-2,5-diazabicyclo[2.2.1]heptan-2-yl)benzamide,

N-hydroxy-4-((lR,4R)-5-(4-(trifluoromethyl)pyridin-2-yl)-2,5-diazabicyclo[2.2.1]heptan-2- yl)benzamide,

N-hydroxy-4-((l S,4S)-5-(4-(trifluoromethyl)pyrimidin-2-yl)-2,5-diazabicyclo[2.2.1 ]heptan-

2-yl)benzamide,

N-hydroxy-N-methyl-4-((lS,4S)-5-p-tolyl-2,5-diazabicyclo[2.2.1]heptan-2-yl)benzamide and

.

85. The compound according to claim 1, represented by the Formula (XI):

and N-oxides, hydrates, solvates, pharmaceutically acceptable salts, prodrugs, polymorphs and complexes thereof, and racemic and scalemic mixtures, diastereomers and enantiomers thereof,

wherein is

and

Q ¹ is selected from the group consisting of-Ci-Cβalkyl, covalent bond, -Co-Cealkyl-O-Co- C ₆ alkyl-,-Co-C ₆ alkyl-NR ₃ -Co-C ₆ alkyl-,-Co-C ₆ alkyl-S(0)o. ₂ -Co-C ₆ alkyl-, -C ₀ -C ₆ alkyl- NR3C(0)-Co-C6alkyl-,-Co-C6alkyl-C(0)NR3-Co-C6alkyl- and -Co-C ₆ alkyl-OC(0)NR3-Co- C ₆ alkyl-.

86. The compound according to claim 85, wherein the moiety

is selected from a radical consisting of

87. The compound according to claim 1, represented by the Formula (XII):

( ) and N-oxides, hydrates, solvates, pharmaceutically acceptable salts, prodrugs, polymorphs and complexes thereof, and racemic and scalemic mixtures, diastereomers and enantiomers thereof,

wherein is

and

Q ² is selected from the group consisting of -Ci-Cβalkyl, covalent bond, -Co-Cealkyl-O-Co- C ₆ alkyl-,-Co-C ₆ alkyl-NR ₃ -Co-C ₆ alkyl-,-Co-C ₆ alkyl-S(0)o- ₂ -Co-C ₆ alkyl-, -C ₀ -C ₆ alkyl- NR3C(0)-Co-C ₆ alkyl-,-Co-C ₆ alkyl-C(0)NR3-Co-C ₆ alkyl- and -Co-C ₆ alkyl-OC(0)NR ₃ -Co- C ₆ alkyl-.

88. The compound according to claim 87, whereinthe moiety

is selected from a radical consisting of

89. The compound according to claim 1, represented by the Formula (XIII):

and N-oxides, hydrates, solvates, pharmaceutically acceptable salts, prodrugs, polymorphs and complexes thereof, and racemic and scalemic mixtures, diastereomers and enantiomers thereof,

wherein is a radical selected from the group consisting of

90. The compound according to claim 1, represent by the Formula (XIV):

and N-oxides, hydrates, solvates, pharmaceutically acceptable salts, prodrugs, polymorphs and complexes thereof, and racemic and scalemic mixtures, diastereomers and enantiomers thereof,

wherein is a radical selected from the group consisting of aryl, heteroaryl, heterocyclyl, cycloalkyl,

wherein each aryl, heteroaryl, cycloalkyl and heterocyclyl is optionally substituted.

91. The compound according to claim 52, wherein are independently selected from the group consisting of phenyl, heteroaryl and heterocyclyl, wherein each phenyl, heteroaryl and heterocyclyl is optionally substituted with one to three substituents independently selected from the group consisting of R ⁴ , wherein

R ⁴ is independently selected from the group consisting of -H, Ci-Cβalkyl, C ₂ -Cealkenyl, C ₂ - C ₆ alkynyl, Ci-C ₆ alkyl-R ³ , -C ₀ -C ₆ alkyl-OR ³ , -Co-Cealkyl-OR ¹ , -C ₀ -C ₆ alkyl-C(O)-OR ³ , -Co-C ₆ alkyl-C(0)NR ³ R ^3a , -CH=CH-C(O)-OR ³ , -CH=CH-C(O)-N(R ³ )(R ^3a ), -N(R ³ )- C(O)-CF ³ , -N(R ³ )-C ₂ -C ₆ alkyl-N(R ³ )(R ^3a ), -C ₀ -C ₆ alkyl-N(R ³ )(R ^3a ), -N(R ³ )-C(O)-Ci- C ₆ alkyl-R ³ , -N(R ³ )-S(O) ₂ -Ci-C ₆ alkyl-R ³ , - S(O) ₂ -N(R ³ )R ^3a , -O-C ₂ -C ₆ alkyl-N(R ³ )(R ^3a ), -O-C ₂ -C ₆ alkyl-OR ¹ , -S-R ³ , -S(O)-Ci-C ₆ alkyl-R ³ , -S(O) ₂ -Ci-C ₆ alkyl-R ³ , C ₃ -C ₆ cycloalkyl, heterocyclyl, C4-Cyheterocyclyl-R ³ , -O-C ₂ -C4alkyl-heterocyclyl, -O-heterocyclyl-C(O)- OR ³ , -O-C ₀ -C ₄ alkyl-aryl, -O-C ₀ -C ₄ alkyl-heteroaryl, -O-C(O)-NR ³ -C ₀ -C ₄ alkyl-aryl, -O- C(O)-NR ³ -C ₀ -C ₄ alkyl-heteroaryl, -O-C ₀ -C ₄ alkyl-heterocyclylaryl, -O-C ₀ -C ₄ alkyl-

heterocyclyl-heteroaryl, -N(R ³ )-C ₂ -C ₄ alkyl-heterocyclyl, -N(R ³ )C(O)N(R ³ )-C ₀ -C ₄ alkyl- heterocyclyl-R ³ , -C ₀ -C ₄ alkyl-OC(O)-R ³ , -C ₀ -C ₄ alkyl-N(R ³ )C(O)-O-R ³ , -C ₀ -C ₄ alkyl- heterocyclyl-C(O)-O-R ³ , -N(R ³ )-C ₂ -C ₄ alkyl-heterocyclyl, F, Cl, Br, I, NO ₂ , -CF ₃ , -OCF ₃ , -OCHF ₂ , -SCF ₃ , -SF ₅₅ -SO ₃ H, -CN, -C ₁ -C ₆ alkylaryl, aryl, heteroaryl, cycloalkyl, -C ₁ -C ₆ alkylheteroaryl, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl moeity of the aformentioned R ⁴ is optionally substituted; wherein each R ³ is independently selected from the group consisting of -H, alkyl, Co-C ₃ alkyl- heterocyclyl, C ₁ -C ₃ alkyl-C ₂ -C ₆ alkenyl, Ci-C ₃ alkyl-C ₂ -C ₃ alkynyl, -C ₂ -C ₄ alkyl-OR ¹ , -C ₂ - C ₄ alkyl-NR ^3b R ^3c , -C ₂ -C ₄ alkyl-NR ¹ R ² , heteroalkyl, C ₀ -C ₆ alkylheteroaryl, C(O)CF ₃ , -C(O)-NH ₂ , -C(O)-NR ^3b R ^3c , -C(O)-NR ¹ R ² , -C(O)-OR ¹ , -S(O) ₂ -NR ¹ R ² , -S(O) ₂ -R ¹ , -C(O)- R ¹ , -C ₃ -C ₆ cycloalkyl, -C ₀ -C ₃ alkyl-C ₃ -C ₇ cycloalkyl, -Ci-C ₆ alkylaryl, aryl, C ₀ -C ₃ alkyl- heteroaryl and heteroaryl, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl moiety is optionally substituted with from one to three independently selected substituents, each R ^3a is independently selected from the group consisting of -H, alkyl, heterocyclyl, C ₂ - Cβalkenyl, C ₂ -C ₃ alkynyl, Q-Czialkyl-OR ¹ , heteroalkyl, heteroaryl, Co-Cβalkylheteroaryl, C(O)CF ₃ , -C(O)-NH ₂ , -C ₃ -C ₆ cycloalkyl, -alkyl-C ₃ -C ₆ cycloalkyl, -Ci-C ₆ alkylaryl, aryl, alkylheteroaryl and heteroaryl, covalent bond, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl moiety is optionally substituted; wherein R ³ and R ^3a , together with the atom to which they are attached, optionally form a heterocyclic ring, wherein the heterocyclyl moiety is optionally substituted; wherein R ^3b and R ^3c , together with the atom to which they are attached, optionally form a heterocyclic ring, wherein the heterocyclyl moiety is optionally substituted; and

R ¹ and R ² are independently selected from the group consisting of -H, Ci-Cβalkyl, aryl, heteroaryl, heterocyclyl, cycloalkyl and a protecting group.

92. The use of a compound according to any of claims 1 to 91 for inhibition of histone deacetylase.

93. A composition comprising a compound according to any of claims 1 to 91 and a pharmaceutically accetable carrier.

94. A method of inhibiting histone deacetylase, the method comprising contacting the histone deacetylase with a compound according to any of claims 1 to 91 or a composition thereof.

95. A method of inhibiting histone deacetylase in a cell, the method comprising contact the cell with a compound according to any of claims 1 to 91 or a composition thereof.

96. A method of treating a polyglutamine (polyQ) expansion disease, comprising administering to an individual in need of treatment a therapeutically effective amount of a compound according to any of claims 1 to 91, or a composition thereof.

97. The method according to claim 96, wherein the disease is selected from the group consisting of Huntington's Disease (HD), Dentatorubralpallidoluysian atrophy (DRPLA), spinal and bulbar muscular atrophy (SBMA), and five spinocerebellar ataxias (SCAl, SCA2, SCA3/MJD (Machado- Joseph Disease), SCA6 and SCA7).

98. The method according to claim 97, wherein the disease is Huntington's Disease.